f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom finance report e roche finance report journey finance report recovery woman shown cover roche finance report year appeared cover report well last year midst receiving treatment breast cancer photographed came powerfully cover year later enjoying life p e n n n v n p r n e r cancer modern care helps advanced analytics enable us roche expanding colla b effective treatments create wealth new data insights orations combining available previously innovative opportunities across strengths unique tools therapies allow woman entire product lifecycle rd partners elevate personalised cover picture carry value chain ultimately improve healthcare new level many life see back cover outcomes patients patientsfinance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business free cash flow concept fully described pages reconciliations ifrs cash flow free cash flow given therefinance brief roche roche group reported strong overall results sales grew constant exchange rates cer ifrs net income increased cer core earnings per share increased cer major driver us tax reform excluding core earnings per share grew sales group sales increased cer chf billion growth chf terms pharmaceuticals sales growth cer due new medicines ocrevus perjeta tecentriq alecensa hemlibra oncology continued growth franchise avastin mabtherarituxan sales fell following biosimilar launches europe biosimilar entry us delayed immunology sales increased led actemraroactemra xolair diagnostics sales showed growth cer immunodiagnostics business major contributor operating results core operating profit increased cer chf billion increase chf terms research development expenditure grew cer chf billion core basis focus oncology neuroscience immunology therapeutic areas research development costs represented group sales ifrs operating results include noncore expenses pretax chf billion major factors chf billion impairment goodwill intangible assets notably chf billion relating intermune acquisition nonoperating results financing costs ifrs decreased chf billion due base effect debt redemption losses income tax expenses ifrs decreased cer chf billion effective core tax rate us tax reform decreasing rate percentage points net income ifrs net income increased cer chf billion increase chf terms core earnings per share increased cer chf terms cash flows operating free cash flow increased chf billion underlying cash generation divisions led increase operating free cash flow cer chf terms free cash flow increased cer chf terms chf billion driven higher operating free cash flow lower income tax payments financial position net working capital decreased cer driven lower inventories pharmaceuticals division net debt decreased chf billion free cash flow covered dividends payments mergers acquisitions net debt percentage total assets credit ratings strong moodys aa standard poors aa shareholder return dividends proposal made increase dividends chf per share represent nd consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles noncurrent liabilities operating segment information current liabilities revenue provisions contingent liabilities net financial expense debt income taxes equity attributable roche shareholders mergers acquisitions subsidiaries associates global restructuring plans noncontrolling interests property plant equipment employee benefits goodwill pensions postemployment benefits intangible assets equity compensation plans inventories earnings per share nonvoting equity security accounts receivable statement cash flows marketable securities risk management cash cash equivalents related parties noncurrent assets list subsidiaries associates current assets significant accounting policies accounts payable report roche management internal control financial reporting statutory auditors report general meeting roche holding ltd basel independent reasonable assurance report internal control financial reporting multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings statutory auditors report general meeting roche holding ltd basel financial review roche group financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche group reported sales growth constant exchange rates cer core operating profit growth ifrs net income increased core eps increased due growth business impact us tax reform sales growth driven new pharmaceuticals medicines compensated growing impacts biosimilar competition europe immunodiagnostics business diagnostics division group improved operating profitability various productivity initiatives supporting launch new products continuing investments research development operating free cash flow chf billion increase due higher cash generated business partly offset higher capital expenditure divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase roche finance report roche group financial review sales pharmaceuticals division chf billion billion new products major growth driver ocrevus perjeta tecentriq alecensa hemlibra together contributing additional chf billion cer new sales ocrevus particular continued strong performance total sales reaching chf billion due continuing growth us launches major european markets perjeta sales chf billion increase higher demand earlystage adjuvant settings us new product sales compensated initial impacts biosimilar entry europe japan sales mabtherarituxan herceptin fell chf billion cer first biosimilar versions mabtherarituxan anticipated come market us mid end first biosimilar versions mabtherarituxan herceptin avastin anticipated come market us second half avastin sales higher mainly due growth china sales growth immunology sales actemraroactemra xolair esbriet increasing lucentis sales grew us increased market share across indications competitive pressure us led fall tarceva sales diagnostics division reported sales chf billion increase cer major growth area centralised point care solutions represented half divisions sales grew led immunodiagnostics business molecular diagnostics sales increased growth cobas liat system blood screening virology businesses diabetes care sales increased ifrs operating profit increased pharmaceuticals division diagnostics division results divisions impacted impairments goodwill intangible assets current year comparative period results include chf billion impairment goodwill intangible assets largest items chf billion relating intermune acquisition impairments goodwill intangible assets chf billion amortisation intangible assets chf billion chf billion expenses global restructuring plans pharmaceuticals divisions core operating profit increased cer sales increase cost sales increased due volumedriven growth manufacturing costs increased royalty expenses notably ocrevus marketing distribution grew due product launches including ocrevus tecentriq research development costs grew especially oncology neuroscience immunology therapeutic areas operating profitability benefited various productivity initiatives ifrs operating profit grew ahead core operating profit due lower restructuring charges also due lower amortisation charges intangible assets operating free cash flow grew underlying business partly offset higher capital expenditure notably chugai diagnostics division core operating profit increased cer also increase sales cost sales grew due increased sales volumes partially offset favourable instrument reagent mixes research development increased due higher spending highmidvolume systems centralised point care solutions development digital clinical decision support products ifrs operating profit grew core operating profit result lower amortisation charges intangible assets operating free cash flow sales decreased due higher net working capital groups operating free cash flow chf billion increase cer due high cash generation business partly offset higher capital expenditure free cash flow chf billion increase chf billion due higher operating free cash flow lower income tax payments financing costs lower ifrs basis chf billion due base impact losses debt redemption prior year income tax expenses lower groups effective core tax rate compared largely due impact us tax reform decreased effective core tax rate percentage points net income increased cer ifrs basis core basis driven cases operating results impact us tax reform excluding impact us tax reform core eps increased results expressed swiss francs negatively impacted appreciation swiss franc us dollar brazilian real partly offset depreciation swiss franc euro net impact results expressed swiss francs compared constant exchange rates negligible sales percentage point impact core operating profit core eps roche finance report financial review roche group income statement change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf see pages definition core results core eps roche finance report roche group financial review mergers acquisitions group implemented amendments ifrs business combinations issued october amendments clarify definition business effect amendments particularly applicable many acquisitions carried roche group since value acquired companies often consists rights single product technology transactions accounted asset acquisitions rather business combinations result acquisition ignyta reassessed accounted asset acquisition annual financial statements rather business combination disclosed interim financial statements details given note annual financial statements business combinations april pharmaceuticals division acquired controlling interest flatiron health inc flatiron health chf billion flatiron health market leader curation development realworld evidence cancer research well oncologyspecific electronic health record software asset acquisitions february pharmaceuticals division acquired controlling interest ignyta inc ignyta chf billion acquisition group obtained rights ignytas lead product candidate entrectinib orally bioavailable cnsactive tyrosine kinase inhibitor patients tumours harbour ros ntrk fusions pharmaceuticals division also completed acquisitions tusk therapeutics ltd jecure therapeutics inc total cash consideration chf billion transactions june group entered merger agreement foundation medicine inc fmi acquire outstanding shares fmis common stock already owned group price usd per share cash fmi fully consolidated subsidiary group since july transaction closed fmi became owned subsidiary group cash consideration purchase public shares including shares issuable fmis outstanding stock incentive plans payment related fees expenses amounted chf billion amounts recorded equity change ownership interest subsidiaries details given notes annual financial statements global restructuring plans group continued implementation various resourcing flexibility plans pharmaceuticals division address various future challenges including biosimilar competition focus areas plans include biologics manufacturing commercial operations product developmentstrategy group also continued implementation several major global restructuring plans initiated prior years notably strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy diagnostics division global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans outsourcing functions shared service centres external providers resourcing flexibility pharmaceuticals divisions commercial operations global product developmentstrategy organisations roche finance report financial review roche group diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated matters costs chf million included divestment subsidiary germany costs related reorganisation molecular diagnostics business chf million spending plans within division chf million site consolidation costs pharmaceuticals divisions strategic realignment manufacturing network chf million mainly related exit manufacturing site clarecastle ireland resourcing flexibility plan biologics manufacturing network incurred costs chf million mainly relating asset impairment severance costs integration costs following ignyta acquisition chf million global restructuring plans resourcing flexibility initiatives pharmaceuticals division incurred costs chf million mainly employeerelated major item chf million plans outsourcing shared service centres external providers plans include plans totalling chf million total global restructuring costs chf billion details given note annual financial statements impairment goodwill intangible assets pharmaceuticals division impairment charges chf billion major item net expenses chf billion relating goodwill intangible assets intermune acquisition group made comprehensive reassessment cashgenerating units used allocating goodwill pharmaceuticals division detailed note annual financial statements reassessment made light following factors ongoing business transformations within pharmaceuticals division acquisition flatiron health effective april transaction fully acquire foundation medicine effective july early adoption amendments ifrs business combinations issued october amendments clarify definition business whether transaction represents substance purchase business single asset group similar assets group reviewed assets liabilities acquired intermune transaction detail including initial valuations reports made purposes acquisition accounting subsequent integration process conclusion review apart intangible asset representing acquired rights esbriet related deferred taxation liabilities assets liabilities recorded groups balance sheet revenue streams parts acquired company synergistic benefits continued operations roche group substance december remaining value group intermune acquisition estimated chf billion solely relates acquired rights esbriet reported groups balance sheet product intangible asset use therefore previously recorded impairment esbriet product intangible asset use partially reversed asset concerned written estimated recoverable value chf billion income chf billion recorded main factor leading increase forecasted cash flows relative previous years longterm forecast due improvement sales expectations full impairment chf billion recorded goodwill intermune acquisition surplus esbriet revenues support carrying value goodwill neither synergistic benefits products therapeutic area accordingly separable recoverable value goodwill estimated zero fully impaired reassessment cashgenerating units used allocating goodwill pharmaceuticals division resulting impairment entries recorded aligns historic transactions transactions onwards use revised ifrs definition business detailed section mergers acquisitions impairments pharmaceuticals division totalled chf billion largest impairment charges chf billion related trophos acquisition follows decision stop development compound acquired decrease contingent consideration provisions mainly due reversal remaining provision related trophos acquisition contributed income chf billion roche finance report roche group financial review diagnostics division diagnostics division recorded impairment charges chf billion major part sequencing business impairment charges chf billion impairments due change commercialisation strategy related products change timelines future product development decrease forecasted cash flows revised sales assumptions addition centralised point care solutions business full impairment chf billion recorded goodwill product intangible assets acquired part constitution medical investors acquisition due decision change commercialisation strategy diagnostics instruments used haematology testing impairment charges chf billion pharmaceuticals division largest item charge chf billion partial impairment esbriet product intangible acquired part intermune acquisition diagnostics division recorded impairment charges chf billion major part sequencing business details given notes annual financial statements legal environmental cases significant developments based development various litigations notably accutane case provisions previously held released resulting income chf million details given note annual financial statements net income earnings per share ifrs net income increased chf terms cer diluted eps increased chf terms cer core net income increased cer core eps increased core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets income impacts accounting merger acquisition transactions alliance arrangements core eps increased cer excluding impact changes us tax rates effective january net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring plans intangible asset amortisation goodwill intangible asset impairment mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect changes us tax rates normalisation equity compensation plan tax benefit core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results roche finance report financial review roche group financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start year swiss franc appreciated many currencies notably euro lesser extent brazilian real partly offset depreciation swiss franc japanese yen us dollar overall negative translation impact total net assets exchange rates used given pharmaceuticals division net working capital decreased cer mainly arose lower inventories due write offs lower inventory levels certain mature products strong sales longterm net operating assets increased mainly result ignyta flatiron health acquisitions offset goodwill impairment charges diagnostics division increase net working capital cer driven increases trade receivables due business growth especially china japan increase inventories instruments pending installation longterm net operating assets diagnostics division decreased following impairment charges goodwill intangible assets decrease net debt due free cash flow chf billion partly offset dividend payments chf billion addition payments chf billion mergers acquisitions payments chf billion acquiring full ownership foundation medicine net pension liability lower chf billion due increase discount rates partially offset changes fair value plan assets net tax liabilities increased mainly due deferred tax effects change net pension liabilities free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid free cash flow see pages definition free cash flow detailed breakdown groups operating free cash flow chf billion increase cer due high cash generation business sales growth exceeding increases cash expenses partly offset higher capital expenditure free cash flow chf billion increase cer compared arose higher operating free cash flow lower income tax payments roche finance report roche group financial review pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow roche finance report financial review roche group sales overview pharmaceuticals division sales therapeutic area change sales sales chf chf cer oncology immunology neuroscience ophthalmology infectious diseases therapeutic areas total sales sales pharmaceuticals division chf billion increase cer new product sales compensated growing impacts biosimilar competition mabtherarituxan herceptin europe sales growth driven continuing rollout new products ocrevus perjeta tecentriq alecensa hemlibra together contributed additional chf billion cer new sales ocrevus particular continued strong performance total sales reaching chf billion billion due continuing growth us strong initial uptake markets notably germany perjeta sales chf billion due increased demand earlystage adjuvant settings us continued growth neoadjuvant metastatic settings europe biosimilar competition negative impact continuing erosion mabtherarituxan europe first biosimilar launches herceptin europe mabtherarituxan herceptin japan sales two products fell chf billion cer europe japan first biosimilar versions mabtherarituxan expected come market us mid end first biosimilar versions mabtherarituxan herceptin avastin anticipated come market us second half total mabtherarituxan herceptin avastin sales chf billion decrease oncology remains divisions largest therapeutic area total growth new products perjeta tecentriq alecensa major contributors avastin sales increased mainly due growth china herceptin sales higher growth us offsetting initial impact biosimilar competition europe mabtherarituxan sales fell following biosimilar launches europe japan recent biosimilar launches limited impact mabtherarituxan herceptin sales main factor sales decline government price cuts tecentriq increase alecensa increase reported continuing postlaunch uptake sales tarceva fell due competitive pressure us sales immunology grew actemraroactemra xolair esbriet increasing lucentis sales grew us driven increased market share across indications infectious diseases sales lower due mainly patent expiry tamiflu us major markets new influenza medicine xofluza launched us late initial sales chf million therapeutic areas sales activasetnkase higher us launch rollout hemlibra medicine haemophilia continued sales chf million mostly us major eu markets japan roche finance report roche group financial review product sales pharmaceuticals division sales change sales sales chf chf cer oncology herceptin avastin mabtherarituxan perjeta kadcyla tecentriq alecensa tarceva xeloda gazyvagazyvaro others total oncology immunology actemraroactemra xolair mabtherarituxan esbriet pulmozyme cellcept others total immunology neuroscience ocrevus madopar others total neuroscience ophthalmology lucentis total ophthalmology infectious diseases tamiflu rocephin others total infectious diseases therapeutic areas activasetnkase mircera neorecormonepogin others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology therapeutic areas roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid arthritis ra well certain types antineutrophil cytoplasmic antibody ancaassociated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales lower driven europe sales fell due launch biosimilars eu markets us mabtherarituxan widely used across nearly approved indications sales increased growth immunology oncology segments also driven subcutaneous formulation first biosimilar launches expected us mid end could come market second half sales also higher international region particularly china due broader market penetration japan sales adversely affected government price cuts limited extent first biosimilar versions launched franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sales change sales sales chf chf cer united states europe japan international total sales perjeta regional sales change sales sales chf chf cer united states europe japan international total sales kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales sales franchise grew chf billion sales herceptin sales higher overall driven growth us international region largely offset falls europe japan factors us growth include rollout new formulation launched longer duration treatment combination perjeta international region growth driven china due broader market penetration herceptin sales europe lower due first biosimilar launches mid biosimilar launches also impact herceptin sales japan sales perjeta grew increased demand regions notably early breast cancer adjuvant setting us europe japan brazil kadcyla sales increased particular international region roche finance report roche group financial review avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma type brain tumour avastin regional sales change sales sales chf chf cer united states europe japan international total sales overall sales increased compared prior year international region sales grew particular broader market penetration china us sales increased due growth frontline ovarian cancer following fda approval june colorectal cancer japan sales increased due steady growth ovarian cancer europe sales declined france largest factor actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth regions driven continued uptake subcutaneous formulation notably recently approved giant cell arteritis indication us japan major contributors sales increase along major eu markets brazil australia xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sales change sales sales chf chf cer united states total sales sales grew driven demand growth chronic idiopathic urticaria expansion overall asthma market xolair remains market leader larger allergic asthma indication ocrevus relapsing forms multiple sclerosis rms primary progressive multiple sclerosis ppms ocrevus regional sales change sales sales chf chf cer united states europe international total sales continuously growing demand indications us growth driven new patients returning patients ocrevus launched us april comparative period includes months sales initial launch phase elsewhere ocrevus showing strong initial uptake launched notably germany roche finance report financial review roche group lucentis wet agerelated macular degeneration wet amd macular oedema following retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sales change sales sales chf chf cer united states total sales us sales grew driven increased market share across indications ongoing rollout prefilled syringes activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sales change sales sales chf chf cer united states international total sales sales higher led us mainly driven broader use hospitals higher number patients treated esbriet idiopathic pulmonary fibrosis ipf esbriet regional sales change sales sales chf chf cer united states europe international total sales sales grew growth us europe part driven launch new tablet formulation tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc sales grew chf million due postlaunch uptake europe notably germany also due launch japan alecensa alkpositive nonsmall cell lung cancer global uptake continued increase sales chf million growth across regions notably us reported sales growth pharmaceuticals division sales region change sales sales chf chf cer united states europe japan international eemea latin america asiapacific regions total sales eastern europe middle east africa united states sales grew led continued uptake ocrevus launched april franchise grew sales increase perjeta particular early breast cancer adjuvant setting well sales growth herceptin lucentis sales increased due ongoing rollout prefilled syringes increased market share approved indications hemlibra alecensa sales showed strong initial uptake sales tarceva fell due competitive pressure mandatory discounts hospitals b drug discount program increased due higher sales notably ocrevus oncology products roche finance report roche group financial review europe sales declined due increasing biosimilar penetration mabtherarituxan eu markets notably germany france uk herceptin sales declined due biosimilar launches major eu markets mid negative impact sales partly offset launches ocrevus tecentriq perjeta well alecensa gazyvagazyvaro particular germany actemraroactemra sales increased due continued uptake subcutaneous formulation japan sales decreased due government price cuts annualised negative effect sales approximately particular mabtherarituxan herceptin sales negatively affected tamiflu sales decreased due lower government stockpiles partially offset higher sales tecentriq launched actemra roactemra alecensa international sales increased driven asiapacific latin america subregions sales china grew due broader market penetration avastin mabtherarituxan herceptin sales brazil increased mainly due higher sales perjeta mabtherarituxan actemraroactemra turkey main drivers growth avastin mabtherarituxan russia sales growth driven higher sales across franchise pharmaceuticals division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales competition generic medicines biosimilars groups pharmaceutical products generally protected patent rights intended provide group exclusive marketing rights various countries however patent rights varying scope duration group may required enter costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars noncomparable biologics reasons could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically results significant reduction net sales relevant product manufacturers typically offer versions lower prices patents expiry always integral part groups business model future growth remain driven innovation latest information clinical studies included annual report pages details groups product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm product sales affected recent patent expiry change chf chf cer comment tamiflu patent expiry us major markets intellectual property biologics involve multiple patents patent timelines individual product therefore difficult give exact date patent expiry biologic medicines group currently estimates basic primary patents major biologic medicines begin expire follows mabtherarituxan around mid us herceptin mid us avastin mid us around eu subcutaneous formulations mabtherarituxan herceptin beyond secondary patent rights roche finance report financial review roche group composition matter patents mabtherarituxan herceptin eu expired first biosimilar versions mabthera rituxan launched europe mid marketed eu countries major factor sales decline product europe first biosimilar versions herceptin launched major eu markets mid japan first biosimilar versions mabtherarituxan herceptin launched sales also adversely affected government price cuts total sales mabtherarituxan herceptin fell chf billion cer europe japan group anticipated first biosimilar versions mabtherarituxan us mid end could come market second half product sales affected biosimilar launches change chf chf cer comment mabtherarituxan europe first biosimilar launches mid herceptin europe first biosimilar launches mid mabtherarituxan japan first biosimilar launches early herceptin japan first biosimilar launches mid based publicly available information competitor companies group currently anticipates following potential developments us still many uncertainties specific biosimilar versions groups biologic medicines approved food drug administration first biosimilar versions mabtherarituxan herceptin avastin could come market us second half sales mabtherarituxan herceptin avastin disclosed previous sections including regional breakdowns summarised table noted previous sections yearonyear movements also driven regular price volume changes biosimilar competition one factor overall picture total mabtherarituxan herceptin avastin sales change sales sales chf chf cer united states europe japan international total sales group derives royalty income us patent known cabilly patent patent expired december therefore certain residual income expiry group expects royalty income significantly lower annual royalty income cabilly patent chf million operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income increased cer royalty income higher due net increase sales across royalty portfolio outlicensing income increased due higher milestone income income chf million sales worldwide rights konakion valcytecymevene excluding brazil japan chf million operating income mainly sale rights established products chugai roche finance report roche group financial review pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales cost sales increased percentage points manufacturing cost sales grew ahead sales growth due volume growth higher inventory writeoffs partially offset favourable product mix royalty expenses higher due increased sales certain products notably ocrevus noncore costs include amortisation impairment intangible assets mainly related esbriet product intangibles results included chf million impairment intangible assets consequently amortisation charges lower end based improved future sales outlook previous impairment partly reversed chf million written back pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer percentage sales decreased comparative period relative decrease resulted various resourcing flexibility initiatives transformation activities costs incurred ensure increased patient access launches ocrevus tecentriq products restructuring costs related resourcing flexibility initiatives sales affiliates mainly amortisation intangible assets includes flatiron health marketing intangibles since april pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales decreased percentage points oncology therapeutic area remained primary area research development tecentriq cancer immunotherapy portfolio key driver neuroscience immunology also represent significant areas spending addition pharmaceuticals division inlicensed pipeline compounds technologies total value chf million capitalised intangible assets impairment charges chf million include impairment chf million due decision stop development compound acquired part trophos acquisition impairment charges relate various portfolio decisions around development compounds different alliance partners roche finance report financial review roche group pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pensions settlement gains losses total ifrs basis core costs increased cer percentage sales remained stable administration costs increased mainly due higher legal service costs business taxes capital taxes fell due decreased costs us branded prescription drug fee restructuring costs relate site divestments impairment charges relate full writeoff goodwill intermune trophos acquisitions mergers acquisitions alliance transactions expenses includes costs related flatiron health acquisition partially offset reversal remaining contingent consideration provisions trophos acquisition income chf million arose release legal provisions notably accutane case roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales external customers pharmaceuticals division total core operating profit operating profit include elimination chf minus million unrealised intercompany gains roche pharmaceuticals chugai chf minus million increase exchange rate japanese yen positive impact approximately chugai results expressed swiss francs groups consolidated results cer reported japanese yen sales chugai external customers lower compared driven government price cuts annualised negative effect sales approximately sales within division increased due increased sales actemraroactemra alecensa roche pharmaceuticals chugais core operating profit increased due income divestment established products higher gross profit sales roche pharmaceuticals partially offset increased research development spending operating free cash flow chugai decreased due capital expenditure new research facilities constructed yokohama roche finance report roche group financial review financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc depreciated significantly us dollar japanese yen resulting positive translation impact net operating assets partly offset appreciation swiss franc brazilian real euro exchange rates used given net working capital net working capital decreased mainly due lower inventories higher net liability receivables payables trade receivables higher result higher sales extended payment terms ocrevus us inventories decreased due higher inventory writeoffs lower inventory levels certain mature products well due strong sales trade payables lower following settlement yearend positions net liability receivablespayables increased due higher accruals rebates chargebacks longterm net operating assets overall longterm net operating assets increased goodwill intangible assets increased due acquisitions ignyta flatiron health partly offset impairments intermune trophos assets major item capital expenditure chugais continued development new research facilities yokohama japan roche investments site development basel kaiseraugst sites switzerland south san francisco campus us well manufacturing investments switzerland germany us roche finance report financial review roche group free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales see pages definition free cash flow detailed breakdown pharmaceuticals divisions operating free cash flow increased cer chf billion main contribution came underlying business operating profit net operating cash adjustments showing increase net working capital lower due increase accruals rebates chargebacks lower inventories capital expenditure higher due land purchase yokohama japan chugais new research facilities final payment genentech property lease option exercise investments intangible assets chf billion higher roche finance report roche group financial review diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow sales diagnostics division reported sales growth cer chf billion main contributor centralised point care solutions led immunodiagnostics business sales growth molecular diagnostics sales increased growth underlying molecular business main growth factors cobas liat system blood screening virology businesses diabetes care sales increased driven growth north america latin america offset lower sales europe advanced staining product portfolio main driver sales growth tissue diagnostics diagnostics division sales business area change sales sales chf chf cer centralised point care solutions molecular diagnostics diabetes care tissue diagnostics total sales roche finance report financial review roche group centralised point care solutions business area major contributor overall divisional results sales growth primarily driven immunodiagnostics business accounts divisions sales clinical chemistry business also factor sales development business growing especially asiapacific due china well europe middle east africa emea growth centralised point care solutions regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales molecular diagnostics overall sales rose underlying molecular business reporting growth sales sequencing business increased growth molecular business sales came cobas liat system blood screening virology businesses regional growth led emea notably south africa due order timing also north america molecular diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales diabetes care sales increased driven north america latin america sales growth mainly came accuchek guide accuchek instant sales decreased emea region mainly resulting market dynamics france diabetes care regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales rose advanced staining portfolio contributing majority growth addition sales increased companion diagnostics primary staining business regionally growth led north america emea asiapacific sales increased china main growth market tissue diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales roche finance report roche group financial review diagnostics division sales region change sales sales chf chf cer europe middle east africa emea asiapacific north america latin america japan total sales centralised point care solutions molecular diagnostics main sales driver emea region divisions largest market north america sales increase spread business areas sales increase asiapacific mainly china grew driven centralised point care solutions sales latin america rose mainly driven centralised point care solutions diabetes care also contributing centralised point care solutions also main factor sales increase japan diagnostics division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products royalties operating income core basis global restructuring plans total ifrs basis expiry late royaltybearing patents polymerase chain reaction pcr technology main factor behind lower royalty income results outlicensing income included settlement patent dispute year global restructuring income related licensing deal portfolio prioritisation initiative diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis roche finance report financial review roche group core costs increased cer sales growth increase due higher sales volumes partially offset favourable instruments reagent mixes core cost sales ratio decreased percentage points global restructuring costs mainly due diagnostics strategy plans amortisation expenses lower due product intangible assets corangeboehringermannheim acquisition fully amortised end impairment charges related impairment intangible assets sequencing business constitution medical investors acquisition diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis increase core costs primarily due higher spending emerging markets asiapacific emea regions additionally increase also results marketing software launch new digital solutions core basis marketing distribution costs percentage sales decreased global restructuring costs consisted organisational changes diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased due higher spending centralised point care solutions portfolio highmidvolume systems also increased spending develop digital clinical decision support products ge healthcare collaboration spending sequencing business also higher percentage sales research development core costs increased impairment charges relate intangible assets sequencing business diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pensions settlement gains losses total ifrs basis core costs remained stable compared increase administration costs main drivers higher personnel costs integration expenses recently acquired businesses viewics mysugr business taxes included income settlement agreement medical device excise tax us percentage sales core costs decrease percentage points impairment charges goodwill sequencing business legal expenses mainly arose increasing litigation costs sequencing business roche finance report roche group financial review financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc appreciated euro resulting negative translation impact net operating assets partly offset depreciation swiss franc us dollar diagnostics division significant net asset position japanese yen depreciation swiss franc japanese yen minor impact exchange rates used given net working capital net working capital increased cer trade receivables increased due growth sales notably china japan inventories increased following high demand emerging markets driving higher purchases instruments held inventories prior installation trade payables increased result optimisation measures including extending payment terms decrease net liability receivablespayables due increases prepayments settlement significant yearend accounts payable accruals longterm net operating assets overall longterm net operating assets decreased cer mainly triggered decrease goodwill intangible assets result impairment charges increase provisions restructuring litigation cases capital expenditure related instrument placements manufacturing site developments china germany roche finance report financial review roche group free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales definition free cash flow detailed breakdown see pages operating free cash flow diagnostics division net cash inflow chf million decrease cer compared cash generation business measured operating profit net operating cash adjustments increased compared core operating profit growth difference part due higher cash proceeds disposals higher noncash depreciation expenses net working capital increased absorbed chf million cash due increases trade receivables inventories mentioned financial position comments capital expenditure chf billion mainly due instrument placements notably china us manufacturing site development china germany roche finance report roche group financial review corporate operating results corporate operating results summary change chf chf cer administration pensions past service costs business taxes capital taxes general items general administration costs core basis global restructuring plans mergers acquisitions alliance transactions legal environmental cases total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results see pages definition free cash flow detailed breakdown general administration costs decreased cer core basis due lower project costs total costs ifrs basis increased due restructuring procurement several corporate functions change net operating assets mainly driven organisational changes resulting transfer chf million assets mainly property plant equipment pharmaceuticals division beginning net working capital lower due increased notes accounts payable abovementioned transfer corporate operating free cash flow includes restructuring activities capital expenditure roche finance report financial review roche group foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy results expressed swiss francs negatively impacted appreciation swiss franc us dollar brazilian real partly offset depreciation swiss franc euro net impact results expressed swiss francs compared constant exchange rates negligible sales percentage point impact core operating profit core eps sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact increase average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yen roche finance report roche group financial review treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position net debt pensions income taxes financial noncurrent assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury activities taxes paid total see pages definition core results see pages definition free cash flow financing costs core financing costs chf million decrease cer compared decrease mainly due base effect losses debt redemption chf million interest expenses including amortisation debt discounts issue costs increased cer chf million due increasing us interest rates net interest cost defined benefit pension plans decreased cer chf million due lower discount rates us end full analysis financing costs given note annual financial statements details debt repayments redemptions given note roche finance report financial review roche group financial income expense core financial income expense net income chf million compared net income chf million net income equity investments chf million higher gains equity investments net foreign exchange results reflect hedging costs losses unhedged positions losses chf million compared net losses chf million full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate decreased percentage points largely due impact us tax reform reduced effective core tax rate percentage points ifrs results show decrease effective tax rate percentage points us tax reform transitional impact results initial estimate effect deferred tax balances tax rate changes trueup adjustment transitional effect included noncore results ifrs results also included impairment goodwill tax deductible hence net effect goodwill intangible assets line table details groups income tax expenses related balance sheet positions given note annual financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect changes us tax rates normalisation equity compensation plan tax benefit groups effective tax rate ifrs basis financial position decrease net debt due free cash flow chf billion partly offset dividend payments chf billion payments mergers acquisitions chf billion buyout minority owners foundation medicine chf billion net pension liability decreased chf billion chf billion due increase discount rates us switzerland germany partially offset decrease fair value plan assets switzerland us net tax liabilities increased mainly due deferred tax effects net pension liabilities december group held financial longterm assets market value chf billion consist mostly holdings biotechnology pharmaceuticals companies acquired part licensing transactions scientific collaborations free cash flow cash outflow treasury activities increased chf billion due higher pension contributions partly offset higher proceeds sales equity investments total taxes paid decreased chf billion due lower income tax payments us following us tax reform partly offset timing tax payments roche finance report roche group financial review cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages operating free cash flow increased cer chf billion major factor increase growth underlying cash generated operations chf billion cash revenues grew cash expenses smaller decrease net working capital compared mainly due lower increase accounts payable capital expenditure chf billion driven site development basel south san francisco well land purchase yokohama japan new research facilities investments intangible assets chf billion increase chf billion compared coming increased inlicensing activities pharmaceuticals division net cash outflow treasury activities increased chf billion due higher pension contributions partly offset higher proceeds sales equity investments taxes paid lower chf billion due lower tax payments us following us tax reform partially offset timing tax payments free cash flow chf billion higher result higher operating free cash flow lower income tax payments roche finance report financial review roche group net debt millions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow dividend payments transactions equity instruments mergers acquisitions net divestments subsidiaries hedging collateral arrangements changes ownership interests subsidiaries currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period definition net debt see net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes net debt position group december chf billion decrease chf billion december decrease due strong free cash flow chf billion partly offset annual dividend payments chf billion payments ignyta flatiron health acquisitions chf billion well payments chf billion taking full ownership foundation medicine issuance redemption repurchase bonds notes see note annual financial statements impact liquid funds impact net debt position roche finance report roche group financial review contractual obligations commitments group obligations commitments set table carrying values shown consolidated balance sheet potential obligations shown discounted riskadjusted amounts denominated foreign currencies translated swiss francs december exchange rates contractual obligations commitments december millions chf potential obligation undiscounted less carrying year years years years total value onbalance sheet debt bonds notes debt contingent consideration provisions accounts payable derivative financial instruments unfunded defined benefit plans total onbalance sheet commitments offbalance sheet capital commitments property plant equipment operating leases contract manufacturing commitments alliance collaboration commitments total offbalance sheet commitments total contractual commitments references notes annual financial statements debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments contingent consideration provisions potential payments arising mergers acquisitions carrying values risk adjusted discounted unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations carrying values discounted future company contributions groups funded plans shown table capital commitments property plant equipment noncancellable commitments purchase construction mainly roche sites basel switzerland south san francisco us operating leases future obligations noncancellable lease contracts group implement ifrs leases point obligations reported balance sheet contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising groups major longterm agreements external contract manufacturing organisations cmos alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing arrangements potential payments alliance partners asset deals within next three years included assuming projects currently development successful potential payments beyond three years included asset deals provisions legal environmental matters included table timing amount cash outflow uncertain contingent development matters question roche finance report financial review roche group pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources expenses groups defined benefit plans chf million chf million defined benefit plans funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans increased compared start year came plans us switzerland increase discount rates partially offset decreases fair value plan assets since end addition plan assets defined benefit obligation funded plans increased chf billion following plan change switzerland funded status pension funds monitored local pension fund governance bodies well closely reviewed group level total cash outflow groups defined benefit plans chf billion compared chf billion higher additional contributions paid groups pension plans us unfunded plans mainly groups german affiliates fully reserved pension obligations used self financing local affiliates operations unfunded liabilities plans decreased mainly due higher discount rate germany full details groups pensions postemployment benefits given note annual financial statements roche finance report roche group financial review roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer healthcare sector outperformed world equity markets characterised increased volatility second half year although swiss market index smi posted losses performance mixed relative major global indices smi underperforming major us indices outperforming european indices roche share performance continued impacted uncertainty impact biosimilars us concerns around us pricing reforms despite positive news flow year strong latestage pipeline peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting would nd consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security also information roche securities given pages roche finance report financial review roche group information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per share debt debt redemptions following redemptions due date june eur billion bonds due date september chf billion bonds due date september chf billion bonds debt issuances following issuances september group issued usd million bonds due september usd million bonds due september september group issued chf million bonds due september chf million bonds due september transactions described note annual financial statements maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf beyond total total translated december exchange rates proceeds bonds notes eur million swapped us dollars therefore consolidated results bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow chf billion included cash generated operations well payment interest tax shortterm financing requirements group commercial paper program us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper notes totalling usd billion outstanding december usd billion longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors aa moodys facilitate efficient access international capital markets information groups debt given note annual financial statements roche finance report roche group financial review financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables chf billion since beginning financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries decrease compared december euro terms group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions since groups trade receivables balance southern europe decreased euro terms liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors aa moodys time roche rated highest available shortterm ratings agencies february moodys upgraded roches rating aa event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper program december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var remained stable interest rate risk interest rate risk arises movements interest rates could affect groups financial result value group equity group may use interest rate derivatives manage interest raterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statements roche finance report financial review roche group international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented ifrs financial instruments ifrs revenues contracts customers including consequential amendments standards group also implemented various minor amendments existing standards interpretations material impact groups overall results financial position new revised standards applied ifrs financial instruments group implemented new standard effective january applied exemption full retrospective application classification measurement requirements including impairment meaning comparative results restated standard deals classification recognition measurement including impairment financial instruments impairment financial assets including trade lease receivables also introduces new hedge accounting model ifrs revenues contracts customers group implemented new standard effective january applied full retrospective method transition since new standard change amounts revenue recognised restatements comparative results necessary new standard contains new set principles recognise measure revenue well new requirements related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration received exchange goods services ifrs business combinations october international accounting standards board issued amendments ifrs business combinations amendments clarify definition business add concentration test aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets amendments mandatory may early adopted effect amendments particularly applicable many acquisitions carried roche group since value acquired companies often consists rights single product technology therefore effective january group early implemented amendments prospective application restatement comparative period information reassessment cashgenerating units used allocating goodwill pharmaceuticals division detailed section impairment goodwill intangible assets resulting impairment entries recorded aligns historic transactions transactions onwards use revised ifrs definition business result amendments ifrs acquisition ignyta reassessed accounted asset acquisition annual financial statements rather business combination disclosed interim financial statements led decrease goodwill chf billion decrease intangible assets chf billion decrease deferred tax liabilities chf billion apart none new standards material impact groups overall results financial position result implementing ifrs group also made presentational change income statement include subtotal revenue created new note revenue note see note annual financial statements details matters new revised standards applied beyond ifrs leases group implement new standard effective january apply cumulative catchup method option transition meaning comparative results restated new standard applied main impact new standard bring operating leases onbalance sheet group currently anticipates new standard result carrying value leased assets increased approximately chf billion lease liabilities increased similar amount date implementation application new standard result part currently reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material see note annual financial statements details roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income oci remeasurements defined benefit plans fair value changes equity investments fair value oci na items never reclassified income statement availableforsale investments na fair value changes debt securities fair value oci na cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total statement comprehensive income adjusted reflect presentational changes required result implementing ifrs financial instruments described note roche finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations asset acquisitions divestment subsidiaries interest dividends received sales equity securities debt securities purchases equity securities debt securities sales purchases money market instruments time accounts three months net investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements changes ownership interest subsidiaries equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december year ended december january implementation ifrs financial instruments january revised net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december equity january revised following implementation ifrs financial instruments described note addition statement changes equity adjusted reflect presentational changes required implementation new standard roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist various performance obligations satisfied different times contracts entered diagnostics division typically include performance obligations instruments including provided leasing arrangements reagents consumables services instruments may sold cash sales transactions discounted prices instruments provided operating lease arrangements entire lease revenue may variable subject subsequent reagents sales sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments licensing fees reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs revenues contracts customers straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating us pharmaceuticals business amounted chf million chf million associated expected sales returns estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non controlling interest consideration transferred business combination management judgement particularly involved assessment whether net assets acquired constitute business recognition fair value measurement roche finance report notes roche group consolidated financial statements roche group intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms management also applies considers appropriate optional concentration test set amendments ifrs business combinations published october aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets impairment property plant equipment goodwill intangible assets december group chf million property plant equipment see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lowerthananticipated product sales could lead shorter useful lives impairment impairment financial assets december group chf million allowance doubtful accounts trade lease receivables see note allowance doubtful accounts based assumptions risk default expected loss rates group uses judgement making assumptions selecting inputs calculation allowance doubtful accounts based companys past experience existing market conditions well forwardlooking estimates end reporting period pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter lifespans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated reliable estimate made provision recorded contingent liabilities disclosed material december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements business combinations could chf million see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops income taxes december group current income tax net liability chf million deferred tax net asset chf million see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations tax positions uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings roche finance report roche group notes roche group consolidated financial statements leases treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes legal safety environmental services subdivisional information also presented roche pharmaceuticals chugai operating segments within pharmaceuticals division divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions intangible assets total research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses roche finance report notes roche group consolidated financial statements roche group pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination results within division operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses net operating assets millions chf assets liabilities net assets december pharmaceuticals diagnostics corporate total operating nonoperating group net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets december roche pharmaceuticals chugai elimination within division pharmaceuticals division roche finance report roche group notes roche group consolidated financial statements information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment intangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue major customers total three us national wholesale distributors represent approximately third groups revenues three us national wholesale distributors mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues pharmaceuticals operating segment residual diagnostics segment roche finance report notes roche group consolidated financial statements roche group revenue disaggregated revenue information disaggregation revenue millions chf revenue revenue contracts revenue contracts revenue customers sources total customers sources total pharmaceuticals division sales therapeutic area oncology immunology neuroscience ophthalmology infectious diseases therapeutic areas sales royalty income income outlicensing agreements income disposal products royalties operating income diagnostics division sales business area centralised point care solutions diabetes care molecular diagnostics tissue diagnostics sales royalty income income outlicensing agreements income disposal products royalties operating income total revenue sources primarily relates lease revenue collaboration income counterparty considered customer income profitsharing arrangements roche finance report roche group notes roche group consolidated financial statements grosstonet sales reconciliation pharmaceuticals division grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics division similar reconciling items much lower amounts pharmaceuticals division sales grosstonet reconciliation millions chf gross sales government regulatory mandatory price reductions contractual price reductions cash discounts customer returns reserves others net sales government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion contractual price reductions include rebates chargebacks result contractual agreements primarily volumebased performancebased cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities see note provisions sales returns recorded balance sheet provisions see note contract balances receivables millions chf accounts receivable current receivables contracts customers noncurrent receivables contracts customers total receivables current receivables mainly include royalty licensing receivables december total receivables include lease receivables considered receivables contracts customers contract assets millions chf accrued income total contract assets roche finance report notes roche group consolidated financial statements roche group contract liabilities millions chf deferred income noncurrent deferred income current total contract liabilities movement contract liabilities millions chf january business combinations revenue recognised included contract liability balance beginning year increases due cash received receivable excluding amounts recognised revenue year divestment subsidiaries currency translation effects december revenue recognised relation performance obligations satisfied previous years increase revenue recognised chf million increase chf million relating performance obligations satisfied previous periods mainly due adjustments sales deduction provisions accruals expected sales returns chargebacks allowances respect previous years remaining performance obligations partially unsatisfied longterm contracts remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts diagnostics division minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales transaction price allocated contracts partially unsatisfied performance obligations millions chf contract liability held contract liability held total thereof expected recognised revenue within one year one five years five years total roche finance report roche group notes roche group consolidated financial statements net financial expense upon transition ifrs see note group elected restate comparative information result information provided current period ifrs basis comparative information ias basis financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans total financing costs financial income expense millions chf net gains losses sale equity securities ias na dividend income availableforsale equity securities ias na writedowns impairments equity securities ias na net gains losses equity investments securities fair value profit loss ifrs na dividend income equity investments securities fair value profit loss ifrs na dividend income equity investments securities fair value oci ifrs na net income equity securities interest income availableforsale debt securities amortised cost ias na net gains losses sale debt securities availableforsale securities amortised costs ias na interest income fair value oci debt securities amortised cost ifrs na net gains losses sale debt securities fair value oci ifrs na net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses gains losses net monetary position hyperinflationary economies net financial income expense associates total financial income expense financial income expense adjusted reflect presentational changes required result implementing ifrs financial instruments described note roche finance report notes roche group consolidated financial statements roche group net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense hyperinflationary economies since july group considered argentina hyperinflationary economy context ias financial reporting hyperinflationary economies cumulative inflation index last three years exceeds measured national wholesaler price index sistema de ndices de precios mayoristas accordingly group reviewed reporting affiliates argentina necessary restated line ias potential adjustments resulting application ias significant impact groups operating results balance sheet adjustment recorded gains losses net monetary position loss chf million resulting loss purchasing power positive net monetary position groups argentinian affiliates income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate decreased largely due decrease us federal tax rate enacted december effective january groups effective tax rate decreased main driver decrease impact us tax reform lowered average expected tax rate mentioned addition us tax reform transitional impact results initial estimate effect deferred tax balances tax rate changes resulted expense chf million increasing group effective tax rate trueup adjustment transitional effect included resulted income chf million roche finance report roche group notes roche group consolidated financial statements groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits deductions us state tax impacts tax unremitted earnings transitional effect changes us tax rates prior year differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans availableforsale investments ias na na na equity investments fair value oci ifrs na na na debt securities fair value oci ifrs na na na cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities current income tax liabilities include accruals uncertain tax positions current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december roche finance report notes roche group consolidated financial statements roche group deferred taxes movements recognised net assets liabilities millions chf property defined plant intangible benefit temporary equipment assets plans differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january implementation ifrs financial instruments january revised business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december deferred tax net assets temporary differences mainly relate accrued liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested purpose financial statements total unremitted earnings group regarded permanently reinvested purpose financial statements chf billion december chf billion roche finance report roche group notes roche group consolidated financial statements mergers acquisitions group implemented amendments ifrs business combinations issued october amendments clarify definition business effect amendments particularly applicable many acquisitions carried group since value acquired companies often largely consists rights single product technology transactions accounted asset acquisitions rather business combinations note expanded renamed mergers acquisitions include transactions accounted business combinations asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations ifrs cash consideration paid asset acquisitions transaction date subsequent additional contingent payments made upon achievement performancerelated development milestones presented line asset acquisitions disclosed separately subsequent consideration performancerelated development milestones transactions treated asset acquisitions recognised intangible assets specific milestones achieved previously intangible assets acquired asset acquisitions included line items purchase intangible assets statement cash flows additions note intangible assets result amendments ifrs see note acquisition ignyta inc reassessed accounted asset acquisition annual financial statements rather business combination disclosed interim financial statements led decrease goodwill chf million decrease intangible assets chf million decrease deferred tax liabilities chf million business combinations flatiron health inc april group acquired controlling interest flatiron health inc flatiron health privately owned us company based new york city flatiron health market leader curation development realworld evidence cancer research well oncologyspecific electronic health record software flatiron health reported pharmaceuticals division total consideration usd million paid cash identifiable assets acquired liabilities assumed set table business combinations net assets acquired millions chf flatiron health intangible assets product intangibles use marketing intangibles use deferred tax assets cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets fair value previously held interest goodwill total consideration cash total consideration fair value flatiron healths technology platform determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate flatiron health valuation performed independent valuer flatiron health accounts receivable comprised gross contractual amounts due chf million expected collectable date acquisition goodwill represents value accelerating progress towards datadriven personalised healthcare cancer advance use realworld evidence set new industry standards oncology research development also represents control premium acquired work force expected synergies none goodwill expected deductible income tax purposes roche finance report notes roche group consolidated financial statements roche group group recognised financial gain chf million fair valuing interest flatiron health held group prior transaction gain included statement changes equity within line item net change fair value financial assets fair value oci transferred retained earnings upon obtaining control directly attributable transaction costs chf million reported pharmaceuticals operating segment within general administration expenses nine months december flatiron health contributed revenue chf million net loss tax chf million results reported pharmaceuticals division group acquisition occurred january management estimates flatiron health would contributed revenue chf million net loss tax chf million information provided illustrative purposes necessarily indicative results combined group would occurred flatiron health actually acquired beginning year indicative future results combined group business combinations mysugr gmbh june group acquired controlling interest mysugr gmbh mysugr private company based vienna austria mysugr reported diagnostics operating segment part diabetes care business total cash consideration eur million viewics inc november group acquired controlling interest viewics inc viewics privately owned us company based san jose california viewics reported diagnostics operating segment total consideration usd million usd million paid cash usd million deferred consideration paid period date control usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million identifiable assets acquired liabilities assumed set table business combinations net assets acquired millions chf mysugr viewics total intangible assets product intangibles use marketing intangibles use cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets fair value previously held interest goodwill total consideration cash deferred consideration contingent consideration total consideration fair value product intangible asset mysugr determined using replacement cost method fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate mysugr viewics valuations performed independent valuers goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business none goodwill expected deductible income tax purposes group recognised financial gain chf million chf million respectively fair valuing interest mysugr interest viewics held group prior transaction gain included financial income expense roche finance report roche group notes roche group consolidated financial statements directly attributable transaction costs chf million reported diagnostics operating segment within general administration expenses impact mysugr viewics acquisitions results diagnostics division group material cash flows business combinations business combinations net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company transaction costs na na na total net cash outflow directly attributable transaction costs business combinations amounted chf million included cash flow operating activities asset acquisitions ignyta inc february group acquired controlling interest ignyta inc ignyta publicly owned us company based san diego california listed nasdaq acquisition group obtained rights ignytas lead product candidate entrectinib orally bioavailable cnsactive tyrosine kinase inhibitor patients tumours harbour ros ntrk fusions ignyta reported pharmaceuticals division total consideration usd million paid cash acquisitions september group acquired controlling interest tusk therapeutics ltd tusk private company based stevenage united kingdom tusk developed antibody novel mode action aimed depleting regulatory tcells suppress immune responses including cancer cells tusk reported pharmaceuticals division november group acquired controlling interest jecure therapeutics inc jecure privately owned us company based san diego california acquisition group obtained rights jecures preclinical portfolio nlrp inhibitors jecure reported pharmaceuticals division total cash consideration paid acquisition date acquisitions chf million additional contingent payments may made based upon achievement performancerelated milestones asset acquisitions net assets acquired millions chf ignyta acquisitions total intangible assets product intangibles available use deferred tax assets cash cash equivalents net assets liabilities net identifiable assets cash total cash consideration roche finance report notes roche group consolidated financial statements roche group cash flows asset acquisitions asset acquisitions net cash outflow millions chf pharmaceuticals diagnostics total cash consideration paid cash acquired company total net cash outflow directly attributable transaction costs acquisitions business combinations amounted chf million included cash flow operating activities foundation medicine transaction april group acquired controlling interest foundation medicine inc fmi treated fully consolidated subsidiary group since date common stock fmi publicly traded listed nasdaq stock code fmi december groups interest fmi june group entered merger agreement fmi acquire outstanding shares fmis common stock already owned group price usd per share cash merger agreement approved board roche special committee independent directors fmi full board directors tender offer launched july july transaction closed fmi became owned subsidiary group accounted full equity transaction cash consideration purchase public shares including shares issuable fmis outstanding stock incentive plans payment related fees expenses amounted usd billion set table amounts recorded equity change ownership interest subsidiaries foundation medicine transaction usd million chf million purchase publicly held shares settlement outstanding stock options vested restricted stock awards directly attributable transaction costs total cash consideration income tax effects change ownership interest subsidiaries roche finance report roche group notes roche group consolidated financial statements global restructuring plans group continued implementation various resourcing flexibility plans initiated pharmaceuticals division address various future challenges including biosimilar competition focus areas plans include biologics manufacturing commercial operations product developmentstrategy group also continued implementation several major global restructuring plans initiated prior years notably strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy diagnostics division global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans outsourcing functions shared service centres external providers resourcing flexibility pharmaceuticals divisions commercial operations global product developmentstrategy organisations diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated matters chf million costs chf million included divestment subsidiary germany costs related reorganisation molecular diagnostics business chf million spending smaller plans within division chf million chf million roche finance report notes roche group consolidated financial statements roche group site consolidation costs pharmaceuticals divisions strategic realignment manufacturing network chf million chf million mainly related exit manufacturing site clarecastle ireland resourcing flexibility biologics manufacturing network incurred costs chf million mainly relating asset impairment severance costs chf million integration costs following ignyta acquisition chf million global restructuring plans resourcing flexibility initiatives pharmaceuticals division incurred costs chf million chf million mainly employeerelated major item chf million plans outsourcing shared service centres external providers chf million plans include plans totalling chf million chf million global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs divestment products businesses gains losses divestment subsidiaries gains losses divestment products businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche finance report roche group notes roche group consolidated financial statements global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total royalties operating income pharmaceuticals diagnostics cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report notes roche group consolidated financial statements roche group property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals divestment subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals divestment subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment charge impairment charges property plant equipment mainly related global restructuring plans see note reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none roche finance report roche group notes roche group consolidated financial statements genentech property purchase option exercise genentech entered master lease agreement mla slough ssf llc slough subsequently acquired health care properties lease property adjacent genentechs south san francisco site developed slough development included total eight buildings construction completed time genentech fully occupied property property lease extension options november genentech exercised purchase option contained mla acquire eight buildings land december group recorded addition land buildings land improvements corresponding liabilities cash outflows group also reclassified finance lease accounting balances previously applied buildings november first closing payment usd million made final closing payment usd million made june see note leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases chf million chf million net book value assets chf million chf million carrying value leasing obligation chf million chf million reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum lease payments payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly property rentals motor vehicles arrangements impose significant restrictions group total operating lease rental expense chf million chf million operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments roche finance report notes roche group consolidated financial statements roche group leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments nil chf million operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties operating leases future minimum lease receipts noncancellable leases millions chf within one year one five years five years total minimum receipts implementation ifrs leases group implement new standard effective january ifrs replace existing leases guidance including ias leases sets principles recognition measurement leases see note details capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations divestment subsidiaries impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals foundation medicine pharmaceuticals product transactions chugai total pharmaceuticals division diabetes care centralised point care solutions molecular diagnostics tissue diagnostics sequencing divisional goodwill total diagnostics division cashgenerating units used allocating goodwill pharmaceuticals division group made comprehensive reassessment cashgenerating units used allocating goodwill pharmaceuticals division reassessment made light following factors ongoing business transformations within pharmaceuticals division acquisition flatiron health effective april transaction fully acquire foundation medicine effective july early adoption amendments ifrs business combinations issued october amendments clarify definition business whether transaction represents substance purchase business single asset group similar assets roche finance report notes roche group consolidated financial statements roche group conclusions reassessment follows within roche pharmaceuticals operating segment goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products typically limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions roche pharmaceuticals operating segment cashgenerating unit goodwill arising technology transactions also roche pharmaceuticals operating segment however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products therapeutic area revenues costs corresponding assets products also taken account acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired chugai remains separate operating segment groups financial reporting remains separate cashgenerating unit goodwill allocated based reassessment group allocated remaining goodwill roche pharmaceuticals operating segment listed basis reallocation historical amounts goodwill arose individual transactions strategic transactions consist genentech foundation medicine flatiron health technology transactions consist therapeutic human polyclonals dutalys santaris product transactions consist glycart tanox intermune trophos diagnostics division divisions business areas sequencing business cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division goodwill arising viewics acquisition monitored divisional level recoverable amount used impairment testing based value use impairment charge pharmaceuticals division assessment potential impairment goodwill pharmaceuticals division carried using cash generating units set impairment charges totalling chf million recorded pharmaceuticals division intermune acquisition charge chf million recorded full writeoff goodwill intermune acquisition made main product acquired original transaction intermunes medicine idiopathic pulmonary fibrosis esbriet idiopathic pulmonary fibrosis progressive disease causes scarring lungs survival rate two three years diagnosis group recorded impairment charge chf million partial impairment esbriet product intangible use main factor leading decrease forecasted cash flows relative previous years longterm forecast due reduction sales expectations group reviewed assets liabilities acquired intermune transaction detail including initial valuations reports made purposes acquisition accounting subsequent integration process conclusion review apart intangible asset representing acquired rights esbriet related deferred taxation liabilities assets liabilities recorded groups balance sheet revenue streams parts acquired company synergistic benefits continued operations roche group roche finance report roche group notes roche group consolidated financial statements group made required assessment potential impairment goodwill arose intermune acquisition using cashgenerating unit identifiable group assets related revenues related costs arose development commercialisation esbriet part groups regular process value use intangible asset representing acquired rights esbriet first tested impairment see note second step goodwill intermune acquisition tested impairment conclusion impairment tests substance remaining value group intermune acquisition estimated chf million solely relates acquired rights esbriet reported groups balance sheet product intangible asset use previously recorded impairment esbriet product intangible asset use therefore partially reversed income chf million recorded asset concerned written estimated recoverable value chf million main factor leading increase forecasted cash flows relative previous years longterm forecast due improvement sales expectations intangible asset continues amortised remaining estimated useful life three years see also note full impairment chf million recorded goodwill intermune acquisition revenues related costs arising development commercialisation esbriet fully utilised impairment testing process support value use esbriet product intangible asset use surplus esbriet revenues support carrying value goodwill neither synergistic benefits products therapeutic area accordingly separable recoverable value goodwill estimated zero fully impaired trophos acquisition charge chf million recorded full writeoff goodwill trophos acquisition made main product acquired original transaction trophos proprietary screening platformgenerated olesoxime tro developed spinal muscular atrophy sma rare debilitating genetic neuromuscular disease commonly diagnosed children group decided stop development compound therefore potential future revenues support carrying value goodwill neither synergistic benefits products franchise accordingly intangible assets relating product fully impaired see note goodwill deemed disposed also fully impaired diagnostics division charge chf million recorded centralised point care business area full write goodwill cmi acquisition made group decided change commercialisation strategy diagnostic instruments used haematology testing led full impairment product intangibles use acquired part cmi acquisition see note therefore goodwill deemed disposed also fully impaired impairment charge impairment charges totalling chf million recorded related charge chf million diagnostics division full writeoff sequencing business goodwill factors leading impairment decrease forecasted cash flows relative previous years longterm forecast due changed assumptions around market penetration pricing reimbursement ii revised time market single molecule sequencing technology addition impairment charges chf million recorded sequencing business product intangibles use acquired part ariosa acquisition see note charge chf million pharmaceuticals division full writeoff goodwill relating seragon acquisition due decision stop development backup compound acquired roche finance report notes roche group consolidated financial statements roche group value use value use calculated using discounted expected cash flow approach posttax discount rate applied projected risk adjusted posttax cash flows terminal value discount rate groups weighted average cost capital cashgenerating units integrated operations across large parts group derived capital asset pricing model using data capital markets including government twentyyear bonds assessing value use cash flow projections based recent longterm forecasts approved management longterm forecasts include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation key assumptions used calculations period cash flow projections included longterm forecasts terminal value growth rate discount rate key assumptions used valueinuse calculations period terminal period terminal cash flow value discount rate cash flow value discount rate projections growth rate tax projections growth rate tax pharmaceuticals division years na years na diagnostics division years years cashgenerating units terminal value growth respective rate exceed longterm projected growth rate relevant market fair value less costs disposal goodwill arising chugai acquisition fair value less costs disposal determined reference publicly quoted price chugai shares sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions would cause carrying values goodwill exceed recoverable amounts december roche finance report roche group notes roche group consolidated financial statements intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group roche finance report notes roche group consolidated financial statements roche group significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use esbriet intermune acquisition roche pharmaceuticals years flatiron health acquisition roche pharmaceuticals years shionogi licence transaction roche pharmaceuticals years foundation medicine acquisition roche pharmaceuticals years kapa acquisition diagnostics years iquum acquisition diagnostics years product intangibles available use entrectinib ignyta acquisition roche pharmaceuticals na biontech licence transaction roche pharmaceuticals na geneweave acquisition diagnostics na technology intangibles use dutalys acquisition roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations asset acquisitions separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product roche finance report roche group notes roche group consolidated financial statements intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lowerthananticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million net impairment reversals recorded related charge chf million due decision stop development five different compounds five different alliance partners assets concerned yet amortised fully written charge chf million due decision stop development compound purchased separately asset concerned yet amortised fully written charge chf million due decision stop development compound acquired part trophos acquisition asset concerned yet amortised fully written charge chf million partial impairment compound purchased separately due delayed timeline asset concerned yet amortised partially written charge chf million following clinical data assessment asset concerned yet amortised fully written charge chf million impairments assets concerned yet amortised fully written previously recorded impairment esbriet product intangible asset use partially reversed income chf million recorded asset concerned written estimated recoverable value chf million main factor leading increase forecasted cash flows relative previous years longterm forecast due improvement sales expectations intangible asset continues amortised remaining estimated useful life three years goodwill impairment charges related intermune acquisition discussed note diagnostics division impairment charges totalling chf million recorded related charge chf million full impairment intangibles use available use related sequencing business mainly acquired part genia capp signature acquisitions factors leading impairment change commercialisation strategy related products change timelines future product development assets concerned partly amortised partly yet amortised fully written charge chf million partial impairment sequencing business product intangibles use acquired part ariosa acquisition factor leading impairment decrease forecasted cash flows following revised sales assumptions asset concerned amortised written estimated recoverable value chf million charge chf million full impairment centralised point care solutions product intangibles use acquired part cmi acquisition result decision change commercialisation strategy diagnostic instruments used haematology testing asset concerned amortised fully written impairment charges pharmaceuticals division impairment charges totalling chf million recorded related charge chf million partial impairment esbriet product intangible use acquired part intermune acquisition asset concerned written estimated recoverable value chf million main factor leading decrease forecasted cash flows relative previous years longterm forecast due reduction sales expectations intangible asset continues amortised remaining estimated useful life four years charge chf million due launch competitor product compound acquired part trophos acquisition asset concerned yet amortised written estimated recoverable value chf million charge chf million due decision stop development one compound alliance partner following assessment clinical nonclinical data asset concerned yet amortised fully written charge chf million due decision stop development one compound acquired part dutalys acquisition asset concerned yet amortised fully written charge chf million due decision stop development one compound acquired part santaris acquisition following clinical data assessment asset concerned yet amortised fully written charge chf million due decision stop development two compounds two different alliance partners assets concerned yet amortised fully written charge chf million following clinical data assessments assets concerned yet amortised fully written roche finance report notes roche group consolidated financial statements roche group diagnostics division impairment charges totalling chf million recorded related charge chf million partial impairment molecular diagnostics product intangibles available use acquired part geneweave acquisition factor leading partial impairment decrease forecasted cash flows following change timelines future product development pricing penetration rate due updated market size assumptions asset concerned yet amortised written estimated recoverable value chf million charge chf million partial impairment sequencing business product intangibles use acquired part ariosa acquisition factor leading impairment decrease forecasted cash flows following revised assumptions pricing penetration rate due market dynamics asset concerned amortised written estimated recoverable value chf million potential commitments alliance collaborations purchase agreements within next three years group party inlicensing similar arrangements alliance partners intangible asset purchase agreements third parties arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments within next three years set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf million roche finance report roche group notes roche group consolidated financial statements accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable allowances doubtful accounts movements recognised allowance millions chf january implementation ifrs financial instruments na january revised na additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expenses recorded marketing distribution costs totalled chf million expense chf million marketable securities upon transition ifrs see note group elected restate comparative information result information provided current period ifrs basis comparative information ias basis marketable securities millions chf ifrs ias ias equity securities availableforsale ias na equity securities fair value profit loss ifrs na na debt securities availableforsale ias na debt securities fair value oci ifrs na na money market instruments time accounts three months availableforsale ias na money market instruments fair value oci ifrs na na time accounts three months amortised costs ifrs na na total marketable securities marketable securities held fund management purposes primarily denominated us dollars euros swiss francs money market instruments contracted mature within one year december roche finance report notes roche group consolidated financial statements roche group debt securities contracted maturity millions chf ifrs ias ias within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents noncurrent assets upon transition ifrs see note group elected restate comparative information result information provided current period ifrs basis comparative information ias basis noncurrent assets millions chf availableforsale investments held fair value ias na availableforsale investments held cost ias na equity investments fair value oci ifrs na na equity investments fair value profit loss ifrs na na loans receivable restricted cash receivables contracts customers receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets equity investments designated fair value oci mainly investments private companies pharmaceutical sector held part groups strategic alliance efforts equity investments classified availableforsale roche finance report roche group notes roche group consolidated financial statements current assets current assets millions chf accrued interest income derivative financial instruments restricted cash cash collateral receivables receivables contracts customers receivables total financial current assets prepaid expenses accrued income taxes recoverable assets total nonfinancial current assets total current assets accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable roche finance report notes roche group consolidated financial statements roche group noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits included genentech property purchase option exercise obligation paid june see note current liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments cash collateral payables accrued chargebacks allowances separately payable accrued royalties commissions accrued liabilities total current liabilities december accrued liabilities included chf million shortterm genentech property purchase option exercise obligation paid june see note roche finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf contingent legal environmental restructuring consideration provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions divestment subsidiaries currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december chf million provisions utilised chf million chf million chf million included cash flows operating activities chf million chf million included cash flows business combinations payments made deferred contingent consideration arrangements see note roche finance report notes roche group consolidated financial statements roche group legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict part regular review litigation matters management reassessed provisions recorded certain litigation matters based development various litigations net increase provisions chf million major element legal expenses chf million net income chf million details major legal cases outstanding disclosed environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland expected costs environmental remediation clarecastle site matters reassessed accordingly environmental provisions increased chf million net net environmental expenses chf million net expense chf million groups procedures environmental protection included annual report pages include actions taken group regard climate change notably groups commitment reduce greenhouse gas emissions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate strategic realignment manufacturing network resourcing flexibility plans address various future challenges including biosimilar competition research development strategic alignment outsourcing functions shared service centres external providers diagnostics division significant provisions associated programmes address longterm strategy details given note contingent consideration provisions group party certain contingent consideration arrangements arising business combinations significant provisions discounted using average discount rate time value money material additional details measurement main movements provisions total potential payments arrangements provided note roche finance report roche group notes roche group consolidated financial statements provisions provisions relate items shown table exception employee provisions timing cash outflows nature uncertain provisions millions chf employee provisions sales returns items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note pharmaceuticals legal cases december provisions legal cases pharmaceuticals division chf million chf million provisions recorded cases settled mainly relating matters listed accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl us district court middle district florida tampa division august mdl closed pendency mdl district court granted summary judgment favour hlr federal ibd cases proceeded affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county february superior court new jersey law division atlantic county held eightday evidentiary hearing whether plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february order july new jersey appellate division reversed order excluding plaintiffs experts testifying accutane causes crohns disease reinstated dismissed cases finding trial court wrongfully barred plaintiffs expert witnesses hlr filed petition review new jersey supreme court granted december august supreme court issued decision whether plaintiffs experts testify accutane causes crohns disease supreme court reversed judgment new jersey appellate division concluded trial court properly excluded experts thereby dismissing cases alleging accutane caused plaintiffs crohns disease plaintiffs appeal crohns disease cases permanently dismissed roche finance report notes roche group consolidated financial statements roche group may superior court entered order granting summary judgment dismissing cases filed new jersey residents basis drug label adequate matter law since july superior court granted hlrs motion summary judgment adequacy label post ingestion cases jurisdictions superior court applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would resulted cases dismissed july new jersey appellate division affirmed dismissal cases reinstated judgments cases based strength hlrs warnings hlr dismissed plaintiffs filed petitions review new jersey supreme court granted december october supreme court issued decision cases reversed judgment new jersey appellate division reinstated cases basis drug label adequate matter law since plaintiffs appeal cases permanently dismissed january october superior court entered orders granting summary judgment dismissing cases failure prove accutane proximately caused ulcerative colitis plaintiffs appealed decisions february march superior court new jersey law division atlantic county held evidentiary hearing whether plaintiffs experts testify accutane causes ulcerative colitis april superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing ulcerative colitis cases subject superior courts april order plaintiffs appealed decisions oral argument expected december hlr defending pending actions approximately cases appeal cases survive appeals additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche strongly disagrees verdict tar appealed consiglio di stato may italian ministry health notified roche spa intention seek damages related matter july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration fine related interest reimbursed roche wins case january european court justice rendered decision five questions referred european court justice consiglio di stato principles defined decision used consiglio di stato render final verdict case outcome matters determined time pdl inhibitor litigation july bristolmyers squibb co bms filed lawsuit genentech inc genentech delaware bms alleges genentechs sale tecentriq infringes us patent bms seeking judgment favour finding wilfulness monetary damages october genentech filed answer counterclaims seeking declaratory judgment invalidity patent trial date scheduled may outcome matter determined time average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time roche finance report roche group notes roche group consolidated financial statements boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us one dismissed case canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time addition matters listed currently provisions recorded potential future obligations confirmed occurrence nonoccurrence uncertain future events obligation measured sufficient reliability hemlibra emicizumab litigation may baxalta inc baxalta gmbh together baxalta subsidiaries shire plc filed patent infringement declaratory judgment patent infringement suit us district court district delaware alleging genentech chugai pharmaceutical co ltd chugai currently imminently would manufacture use sell offer sale import us hemlibra emicizumab would infringe baxaltas us patent baxalta seeking judgment infringement injunctive monetary relief attorneys fees costs expenses may genentech served complaint genentechs response counterclaims complaint filed june june chugai waived service september chugai filed motion dismiss complaint lack personal jurisdiction december baxalta filed request preliminary injunction genentech inhibitor patients would subject injunction hearing held us district court district delaware june hearing baxalta withdrew request preliminary injunction inhibitor patients june baxalta submitted new proposed preliminary injunction order genentech would permitted sell hemlibra inhibitor patients noninhibitor patients currently hemlibra whether clinical trials selected noninhibitor patients additional medically diagnosed condition rendered factor viii therapies impracticable august us district court ruled baxalta denying request injunction september chugai dismissed case trial scheduled september march case brought baxalta chugai japan tokyo district court ruled favour chugai notably hemlibra infringe baxaltas patent may baxalta appealed decision november food drug administration fda approved hemlibra haemophilia inhibitors use us october fda approved use hemlibra us treatment noninhibitor patient population outcome matter determined time securities litigation june class action filed us district court district new jersey roche holding ltd two current officers lawsuit brings claims federal securities laws connection groups public disclosures particular respect matters relating two roches drugs herceptin perjeta september district court dismissed case concluding nothing misleading public disclosures subsequently plaintiffs filed second amended complaint group vigorously defend matter outcome matter determined time iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device companies named defendants complaint filed federal district court district columbia us behalf us servicemembers relatives allege killed injured iraq iraq lawsuit complaint alleges defendants violated us antiterrorism act various state laws providing funding terrorist organisations sales practices pursuant pharmaceutical andor medical device contracts iraqi ministry health addition fhlr received inquiry july us department justice connection anticorruption investigation relating activities iraq including interactions iraqi government certain matters alleged iraq lawsuit group vigorously defend matter outcome matter determined time arbitration chugai may medical research council lifearc formerly medical research council technology requested arbitration chugai pharmaceutical co ltd arbitrator appointed august april united kingdom research innovation ukri established became successor title medical research council current claimants arbitration lifearc ukri sums sought chugai alleged breach obligations collaboration agreement dated august connection development humanised antihuman il receptor monoclonal antibody actemraroactemra claimed chugai obliged pay royalties claimants pursuant collaboration agreement chugai considers claims without merit chugai vigorously defend arbitration outcome matter determined time roche finance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt changes financing cash flows net gains losses redemption repurchase bonds notes amortisation debt discount financing costs business combinations net foreign currency transaction gains losses currency translation effects changes foreign exchange rates changes fair values hedging instruments changes december bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche finance report roche group notes roche group consolidated financial statements bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usbc notes due september principal usd billion isin usba notes due september principal usd billion isin usbb notes due january principal usd billion isin usbm notes due september principal usd billion isin usbn na notes due september principal usd billion isin usbe na notes due november principal usd billion isin usbj na notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na notes due september principal usd billion isin usbp na notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na us dollar notes floating rate notes due september principal usd billion isin usbd na notes due september principal usd billion isin usaz na euro medium term note programme fixed rate notes due june principal eur billion isin xs na notes due march principal usd billion isin xs notes due march principal eur billion outstanding eur billion isin xs notes due february principal eur billion isin xs na notes due august principal gbp billion outstanding gbp billion isin xs na notes due february principal eur billion isin xs na swiss franc bonds fixed rate bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch na genentech senior notes senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes roche finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes september group completed offering chf billion chf billion fixed rate bonds coupon respectively bonds mature september september respectively bonds listed six swiss exchange group received chf million aggregate net proceeds issuance sale fixed rate bonds september group completed offering usd billion usd billion fixed rate notes coupon respectively notes mature september september respectively group received chf million aggregate net proceeds issuance sale fixed rate notes issuance bonds notes march group completed offering chf billion fixed rate bonds issued three tranches chf million bonds zero coupon matured september chf million bonds coupon mature september chf million bonds coupon mature march bonds listed six swiss exchange group received chf million aggregate net proceeds issuance sale fixed rate bonds redemption repurchase bonds notes redemption euro notes due date june group redeemed fixed rate notes principal amount eur billion cash outflow chf million plus accrued interest effective interest rate bonds redemption swiss franc bonds due date september group redeemed fixed rate bonds principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds due date september group redeemed bonds zero coupon principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds roche finance report roche group notes roche group consolidated financial statements redemption repurchase bonds notes redemption swiss franc bonds due date march group redeemed fixed rate bonds principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds redemption us dollar notes due date september group redeemed fixed rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes due date september group redeemed floating rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes redemption pound sterling notes november group completed tender offer repurchase gbp million fixed rate notes due august cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes redemption euro notes november group completed tender offer repurchase eur million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes additional chf million gain recognised part net gains losses redemption repurchase bonds notes coming termination crosscurrency swap used hedge tendered portion euro notes cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf us dollar notes swiss franc bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme pound sterling notes euro medium term note programme euro notes us dollar notes swiss franc bonds total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd total committed credit lines available backstop supporting commercial paper program usd billion december maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding roche finance report notes roche group consolidated financial statements roche group movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies average interest rate december amounts outstanding chf million chf million due within one year equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense roche finance report roche group notes roche group consolidated financial statements changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january implementation ifrs financial instruments january revised net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax december equity attributable roche shareholders january revised following implementation ifrs financial instruments described note addition statement changes equity adjusted reflect presentational changes required implementation new standard roche finance report notes roche group consolidated financial statements roche group genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced chf billion chf billion allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis holding ag basel owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result total distribution shareholders chf million subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf million fair value nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche finance report roche group notes roche group consolidated financial statements reserves fair value reserve december fair value reserve represents cumulative net change fair value financial assets fair value oci previously availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs subsidiaries associates chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roche finance report notes roche group consolidated financial statements roche group roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery foundation medicine april group acquired controlling interest foundation medicine inc fmi publicly owned us company based cambridge massachusetts entered investor rights agreement research development collaboration agreement several commercial collaboration agreements fmi treated fully consolidated subsidiary group since date december groups interest fmi common stock fmi publicly traded listed nasdaq stock code fmi fmi prepared financial statements accordance us gaap filed quarterly basis sec due certain consolidation entries differences fmis standalone us gaap results results fmi consolidated roche group accordance ifrs june group entered merger agreement fmi acquire outstanding shares fmis common stock already owned group price usd per share cash tender offer launched july july transaction closed fmi became owned subsidiary group accounted full equity transaction see note dividends dividends distributed third parties holding fmi shares roche finance report roche group notes roche group consolidated financial statements associates senseonics holding inc senseonics treated associate group december groups interest senseonics december group exclusive distributor senseonics eversense product solution major markets outside us opinion management gives group potential exercise significant influence operations senseonics business common stock senseonics publicly traded listed new york stock exchange nysemkt stock code sens senseonics prepares financial statements accordance us gaap filed quarterly basis sec group accounts senseonics using equity method based senseonics financial statements publicly available groups share senseonics results profit chf million included financial income expense see note carrying value groups share senseonics net assets december asset chf million included noncurrent assets see note divestment subsidiaries divestment subsidiaries november group sold wholly owned subsidiary roche diagnostics solutions gmbh berlin germany third party total consideration eur million deferred consideration become due november total loss divestment chf million reported global restructuring costs diagnostics operating segment included general administration group received deferred consideration eur million sale former subsidiary segrate site italy third party divestment subsidiaries february group sold wholly owned subsidiary roche carolina inc florence us third party part previously announced pharmaceuticals divisions strategic realignment manufacturing network september group sold wholly owned subsidiary segrate site italy third party part previously announced pharmaceuticals divisions strategic realignment manufacturing network total gains losses divestments shown table gains losses divestment subsidiaries millions chf cash consideration deferred consideration total consideration property plant equipment goodwill cash cash equivalents provisions net assets liabilities currency translation foreign operations transferred income statement total net assets disposed provisions accruals residual obligations retained group gains losses divestment subsidiaries cash flow divestment subsidiaries millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration received deferred consideration received cash divested company total net cash inflow roche finance report notes roche group consolidated financial statements roche group noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments ias na equity investments fair value oci ifrs na debt securities fair value oci ifrs na cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests roche finance report roche group notes roche group consolidated financial statements employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plan us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation roche finance report notes roche group consolidated financial statements roche group pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility following plan change employee profitsharing plan mitarbeitergewinnbeteiligung longer qualifies defined contribution plan defined benefit plan resulted additions plan assets defined benefit obligation approximately chf billion operating income chf million recorded past service cost plan change switzerland amount chf million recorded pharmaceuticals division chf million diagnostics division chf million corporate past service income recorded within general administration pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans underfunding would normally remedied additional company contributions payments made group usd million usd million increase payments compared due accelerated contributions benefit higher tax deduction group entered annuity buyout agreement insurance company paid usd million plan assets settle defined benefit obligation retired employees led settlement loss usd million pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contributionbased minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan relation restructuring manufacturing site clarecastle ireland group entered annuity buyout agreement insurance company paid eur million plan assets settle defined benefit obligation retired employees addition transfer value payments eur million plan assets made deferred employees settle defined benefit obligation group recorded settlement loss eur million transactions postemployment benefit opeb plans represent approximately groups defined benefit obligation consist postemployment healthcare life insurance schemes mainly us plans mainly unfunded andor contributory employees group reimbursing retired employees directly financial resources groups major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans usd million none december ifrs funding status including reimbursement rights funded opeb plans us roche finance report roche group notes roche group consolidated financial statements defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement funding status funding groups various defined benefit plans responsibility respective senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations ifrs funding status funded defined benefit plans improved reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities roche finance report notes roche group consolidated financial statements roche group plan assets responsibility investment strategies funded plans respective senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations post employment benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets loss chf million gain chf million recognition plan assets limited present value economic benefits available refunds plans reductions future contributions plans defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january additions interest income plan assets remeasurements plan assets currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property primarily private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf million roche finance report roche group notes roche group consolidated financial statements defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee result proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contributionbased minimum guarantee remain open new employees defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january additions current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years roche finance report notes roche group consolidated financial statements roche group actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour average life expectancy assumed individual age follows defined benefit plans average life expectancy age major schemes years male female country mortality table switzerland bvg projected cmi model united states rp projected mp germany heubeck tables g projected cmi model rp tables projected mp data used heubeck tables g used mortality assumptions used pension plans switzerland based bvg applying continuous mortality investigation cmi model longterm rate used longevity improvements december group used mortality assumptions pension plans germany heubeck tables g applying cmi model longterm rate longevity improvements financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us roche finance report roche group notes roche group consolidated financial statements sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf increase decrease defined benefit obligation life expectancy year increase discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional contributions related uk defined benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plans roche finance report notes roche group consolidated financial statements roche group equity compensation plans group operates several equity compensation plans including separate plans chugai foundation medicine ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai foundation medicine plans total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai foundation medicine plans exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive non voting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche finance report roche group notes roche group consolidated financial statements roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offers future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme currently operates annual threeyear cycles roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number shares nonvoting equity securities individual award granted amount shares nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two shares non voting equity securities value adjustment depending upon achievement performance targets roche finance report notes roche group consolidated financial statements roche group roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equity settled awards sevenyear duration vest phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date roche finance report roche group notes roche group consolidated financial statements fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche roche roche stocksettled stock restricted performance roche appreciation rights stock unit plan share plan option plan progressively cliff vesting cliff vesting progressively vesting period years years years years contractual life years na na years number granted year thousands weighted average fair value chf model used binomial market pricea monte carlob binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history riskfree interest rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf roche finance report notes roche group consolidated financial statements roche group diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics divisions calculated using indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns net gain loss disposal products adjustments cash generated operations roche finance report roche group notes roche group consolidated financial statements cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders dividend withholding tax total liabilities arising financing activities movements carrying value recognised assets liabilities millions chf cash flows noncash changes foreign outflow financing business fair value exchange january inflow costs combinations rates december debt interest payable derivative financial instruments net cash collateral receivables payables net total debt interest payable derivative financial instruments net cash collateral receivables payables net total significant noncash transactions significant noncash transactions none roche finance report notes roche group consolidated financial statements roche group risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part longterm forecasting controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits types authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets group considers financial asset default counterparty unlikely pay obligations group full assessing whether counterparty default group considers qualitative quantitative indicators eg overdue status based data developed internally certain financial assets also obtained external sources major part groups receivables past due days relate public customers risk default public customers considered low group reasonable supportable information demonstrate lagging default criterion appropriate particular customer segment accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts group uses allowance matrix estimate allowance doubtful accounts trade receivables expected credit loss ecl rate based groups historical experience groups expectation economic conditions period receivables expected paid roche finance report roche group notes roche group consolidated financial statements customer credit risk exposure based accounts receivable days overdue ifrs millions chf overdue overdue overdue credit total current months months year impaired december gross carrying amount groups expected credit loss rate allowance doubtful accounts ageing accounts receivable impaired ias millions chf december neither overdue impaired overdue month overdue months overdue months overdue months overdue year total accounts receivable december groups combined trade receivables balance three us national wholesale distributors mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables chf billion chf billion public private customers countries group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue net allowances doubtful accounts allowances nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total cash marketable securities excluding equity securities december group cash marketable securities excluding equity securities chf billion chf billion subject policy restricting exposures high quality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly roche finance report notes roche group consolidated financial statements roche group cash cash equivalents held banks financial institutions predominantly rated investment grade respectively based moodys standard poors ratings cash shortterm time deposits subject rules limit groups exposure individual financial institutions impairment cash cash equivalents measured month expected credit losses ecl basis reference external credit ratings counterparties reflect short maturities exposures group considers cash cash equivalents low credit risk based external credit ratings investments marketable securities excluding equity securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity counterparties credit rating least baa moodys bbb standard poors credit risk counterparties external ratings investment grade nonrated closely monitored reviewed individual basis rating analysis cash marketable securities excluding equity securities market values millions chf ifrs ias fair value amortised oci costs month month available loans total ecl ecl total forsale receivables aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amounts loss allowance loss allowance related fair value oci affect carrying amount marketable securities excluding equity securities booked corresponding oci reserve instead debt securities amortised cost fair value oci investment grade therefore considered low risk thus impairment allowance determined month expected credit losses ecl reference external credit ratings counterparties debt securities group observed significant increase credit risk would require application lifetime expected credit losses impairment model material impact resulting revised impairment approach ifrs addition material movements loss allowance master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses financial assets excluding equity investmentssecurities ifrs amounted chf million total impairment losses availableforsale assets ias amounted chf million liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit lines various financial institutions totalling chf billion chf billion chf billion serve backstop line commercial paper program roche finance report roche group notes roche group consolidated financial statements remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility mainly pharmaceuticals division future minimum takeorpay commitments within agreements total potential commitment group chf billion december chf billion market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remained largely stable foreign exchange component decreased due favourable exposure mix price component arises mainly movements equity security prices decreased due lower volatility held assets roche finance report notes roche group consolidated financial statements roche group foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro groups foreign exchange risk management strategy preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously immunise unfavourable developments foreign exchange rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments shortterm debt groups interest rate risk management strategy optimise net interest result group may use forward contracts options interest rate swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined chugai management roche finance report roche group notes roche group consolidated financial statements financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments ifrs millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost liabilities value fair value december ifrs noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities carrying value fair value financial instruments ias millions chf fair value total available hedging fair value loans financial carrying forsale instruments designated receivables liabilities value fair value december ias noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities roche finance report notes roche group consolidated financial statements roche group fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total december ifrs marketable securities equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value december ias marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value fair value hierarchy adjusted reflect presentational changes required result implementing ifrs financial instruments described note level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date equity investments fair value oci fair value profit loss previously availableforsale investments based valuation model uses recently published observable market data group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none time accounts three months accounted amortised cost ifrs result longer included fair value hierarchy analysis accounted availableforsale ias therefore included fair value hierarchy roche finance report roche group notes roche group consolidated financial statements level fair values details determination level fair value measurements set contingent consideration arrangements millions chf january arising business combinations utilised settlements total unrealised gains losses included income statement unused amounts reversed recorded within general administration additional amount created recorded within general administration discount unwind included financing costs total gains losses included comprehensive income currency translation effects december contingent consideration provisions decreased mainly due reversal provisions payment milestones chf million income net mainly reversal remaining provision related trophos acquisition payments chf million made milestones related dutalys acquisitions contingent consideration arrangements group party certain contingent consideration arrangements arising business combinations fair values determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rates higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment dutalys roche pharmaceuticals santaris roche pharmaceuticals trophos roche pharmaceuticals geneweave diagnostics genia diagnostics ariosa diagnostics others various diagnostics december roche finance report notes roche group consolidated financial statements roche group derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements november group completed tender offer repurchase eur million fixed rate notes due march result hedge terminated cash received group counterparty movements cash collateral receivable accrued liability millions chf january net cash delivered group fair value currency translation effects december hedge accounting upon transition ifrs see note group elected restate comparative information result certain information required ifrs provided described groups risk management strategy hedge transaction exposures arising foreign currency flows monetary positions held foreign currencies well generate appropriate mix fixed floating rate exposures level hedging depends market conditions business requirements group group designates annually specific interest rate risk management objective ensure predetermined range interest rate risk exposure floating rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments reporting date ensure economic relationship exists hedged item hedging instrument group performs qualitative assessment hedge effectiveness using critical terms match method critical terms hedged items hedging instruments match group concludes risks hedged hedged items hedging instruments sufficiently aligned inherent mismatch hedging relationship hedge ratio applies actual quantities hedged hedge accounting roche finance report roche group notes roche group consolidated financial statements accounting treatment sources ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential sources ineffectiveness assessment method interest rate foreign exchange rate fluctuations cash flow hedge counterparty credit risk critical terms match foreign exchange rate fluctuations cash flow hedge lower volume hedged items critical terms match counterparty credit risk interest rate fluctuations fair value hedge counterparty credit risk critical terms match ineffective portion hedge accounting recognised income statement included financial income expense measured using hypothetical derivative method cash flow hedges cumulative dollar offset method fair value hedges december none potential sources ineffectiveness individually collectively resulted material amounts actual ineffectiveness reported hedge accounting relationships table shows fair values nominal amounts derivative financial instruments including range timing nominal amount hedging instruments designated hedging instruments cash flow hedge fair value hedge december group following cash flow hedges fair value hedges designated qualifying hedge relationship fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total fair values derivative financial instruments used hedge accounting included current assets see note current liabilities see note groups approach managing market risk including interest rate risk foreign currency risk discussed market risk section note cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro december instruments recorded net fair value liability chf million chf million ineffective portion chugai entered forward exchange contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value assets chf million fair value liabilities chf million fair value assets chf million ineffective portion carrying amount items designated hedged items cash flow hedging relationship millions chf assets liabilities bonds notes risk hedged crosscurrency swaps interest rate foreign exchange rate fluctuations bonds notes inventories risk hedged forward exchange contracts foreign exchange rate fluctuations inventories roche finance report notes roche group consolidated financial statements roche group hedging reserve continuing hedging relationships millions chf cross forward currency exchange total swaps contracts january gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation effects december entire amount transferred income statement reported financial income expense hedging relationships hedge accounting longer applied changes hedging reserve within equity shown note expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow fair value hedges group entered interest rate swaps hedge exposure changes fair value fixedterm debt instruments respect benchmark interest rate december instruments recorded fair value liabilities chf million chf million fair value assets chf million chf million fair value adjustments chf million recorded interest rate swaps chf million fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments groups approach managing market risk including interest rate risk discussed market risk section note carrying amount items designated hedged items fair value hedging relationship millions chf fair value fair value adjustments adjustments liabilities cumulative current year bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes net investment hedges group net investment hedges roche finance report roche group notes roche group consolidated financial statements related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling chf chf dr oeri received remuneration totalling chf chf transactions group individual members shareholder group exception dr jrg duschmal worked postdoc roche end september subsidiaries associates listing group subsidiaries associates included note listing excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees dr franz members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members cec members cec also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring partway year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions roche finance report notes roche group consolidated financial statements roche group detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid members corporate executive committee millions chf roche connect transactions former members board directors corporate executive committee pensions totalling chf million paid group former corporate executive committee members chf million defined benefit plans transactions group various defined benefit plans employees group described note roche finance report roche group notes roche group consolidated financial statements list subsidiaries associates following listing group subsidiaries associates excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million united states senseonics holdings inc germantown usd stock exchange new york stock exchange nysemkt stock code sens isin usu market capitalisation usd million nonlisted companies share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars roche diabetes care argentina sa tigre ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited north ryde aud roche products pty limited dee aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk usd belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad syntex pharmaceuticals international limited hamilton usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai ltd shanghai usd roche diagnostics suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche services americas sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostics egypt trading sae giza egp el salvador productos roche el salvador sa de cv antiguo cuscatlan svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur fmi germany gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate services mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur signature diagnostics gmbh potsdam eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sociedad annima guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostics india private limited mumbai inr roche products india private limited mumbai inr viewics india private limited pune inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd hod hasharon ils roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions italy roche diabetes care italy spa monza eur roche diagnostics spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur macedonia roche makedonija dooel skopje eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd quatre bornes mur mexico productos roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab productos roche interamericana sa prisa panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub saudi arabia roche products saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions south africa kapa biosystems pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostics proprietary limited midrand zar roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostics sl sant cugat del valls eur roche farma sa madrid eur sweden roche ab solna sek roche diagnostics scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care switzerland ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim sirketi istanbul try roche diagnostics turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diabetes care middle east fzco dubai aed roche diagnostics middle east fzco dubai aed roche pharmaceuticals middle east fzco dubai aed united kingdom intermune holdings limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics limited burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp tusk therapeutics limited welwyn garden city gbp roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapolis usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine securities corporation cambridge usd foundation medicine inc cambridge usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd hoffmannla roche inc little falls usd surviving corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc san diego usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc san diego usd kapa biosystems inc wilmington usd memory pharmaceuticals corp little falls usd mysugr inc encinitas usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche health solutions inc indianapolis usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequencing solutions inc pleasanton usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc san jose usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche vietnam company limited ho chi minh city usd share capital less local currency units roche finance report notes roche group consolidated financial statements roche group significant accounting policies consolidation policy subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income revenue sales revenue sale goods supplied product sales services rendered recoded sales sales recognised promise customer contract performance obligation satisfied transferring control promised goods services customer control promised good service refers ability direct use obtain substantially remaining benefits goods services control usually transferred upon shipment delivery upon receipt goods customer services rendered accordance delivery acceptance terms agreed customers goods subject installation instruments sold diagnostics division sales generally recognised upon completion installation customers site customer acceptance amount sales recognised transaction price based consideration group expects receive exchange goods services excluding amounts collected behalf third parties value added taxes taxes directly linked sales contract contains one performance obligation transaction price allocated performance obligation based relative standalone selling prices roche finance report roche group notes roche group consolidated financial statements instruments diagnostics division may sold together goods reagents consumables well services single contract several contracts combined revenue recognition purposes sales recognised upon satisfaction performance obligations contract instruments either sold cash instalment sales transactions otherwise made available customers finance lease operating lease transactions finance leases arrangements group transfers substantially risks rewards ownership customer treated finance lease arrangements sales finance leases recognised amounts represent fair value instrument approximates present value minimum lease payments arrangement interest rates embedded finance lease arrangements approximately market rates sales finance leases comparable revenue outright sales finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest rate method recorded royalty operating income operating leases sales operating leases recognised straightline basis lease term lease revenue entirely variable subject subsequent reagent sales performance obligation deliver reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise contracts distributors sales recognised goods physically transferred distributor consignment arrangement distributor acts agent cases sales recognised control goods transfers endcustomer distributors commissions presented within marketing distribution commissions similar payments distributors acting principals deducted sales unless payments exchange distinct service consideration received group exchange goods services may fixed variable variable consideration recognised considered highly probable significant revenue reversal occur underlying uncertainty related variable consideration subsequently resolved common elements variable consideration pharmaceuticals division listed government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us contractual price reductions include rebates chargebacks result contractual agreements primarily volumebased performancebased cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities provisions sales returns recorded balance sheet provisions group recognises deferred income contract liability consideration received become receivable group transfers promised goods services customer deferred income mainly relates remaining performance obligations goods free charge certain patient access similar programmes reagents consumables services remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing non cancellable otherwise enforceable contracts mainly associated contracts minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales roche finance report notes roche group consolidated financial statements roche group royalty operating income royalty operating income includes royalty income income outlicensing agreements income disposal products items royalty income earned licence recognised underlying sales recorded licensee income outlicensing agreements typically arises receipt upfront milestone similar payments third parties granting licence product technologyrelated intellectual property ip outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing licences granted usually rights use ip generally unique therefore basis allocating revenue performance obligations makes use residual approach upfront payments licensing fees usually recognised upon granting licence unless income shall deferred performance obligations using residual approach deferred income released recognised revenue performance obligations satisfied milestone payments typically received upon reaching specific scientific milestone development milestone upon achieving certain annual sales milestone commercial milestone development milestone income recognised point time highly probable respective milestone event criteria achieved risk revenue reversal considered remote commercial milestone income accrued recognised revenue highly probable annual sales milestone reached period payments received disposal product similar rights recognised revenue upon transfer control rights extent payments relate performance obligations portion deferred using residual approach recognised revenue activities manufacturing services rendered income profitsharing arrangements collaboration partners recognised underlying sales cost sales recorded collaboration partners also included income services rendered usually part groups primary business activities extent revenue recorded sales recognised control transfers performance obligations satisfied cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred post acquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset roche finance report roche group notes roche group consolidated financial statements employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service cost charged appropriate income statement heading within operating results past service cost including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity roche finance report notes roche group consolidated financial statements roche group property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee finance leases exist substantially risks rewards ownership transferred group finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method operating leases exist substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased third party customers finance operating lease arrangements transactions may entered separate contracts combined contracts including reagents consumables services finance leases finance lease assets reported receivables amount equal net investment lease sales finance leases recognised amounts represent fair value instrument approximates present value minimum lease payments arrangement finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income operating leases sales operating leases recognised straightline basis lease term lease revenue entirely variable subject subsequent reagent sales performance obligation reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise mergers acquisitions business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses roche finance report roche group notes roche group consolidated financial statements asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations date acquisition group initially recognises individual identifiable assets acquired liabilities assumed cost representing cash consideration paid date acquisition allocated individual identifiable assets liabilities date acquisition subsequent consideration performancerelated development milestones recognised intangible assets specific milestones achieved transactions give rise goodwill directly attributable acquisitionrelated costs expensed incurred within general administration expenses goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate long term interest rate impairment loss arises useful life asset reviewed necessary future depreciation amortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cash generating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process intermediates includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses roche finance report notes roche group consolidated financial statements roche group receivables including accounts receivable policy applicable january receivables carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances receivable represents right consideration unconditional excludes contract assets allowance doubtful accounts recorded expected credit losses term receivables estimates based specific indicators ageing customer balances specific credit circumstances groups historical loss rates category customers adjusted forwardlooking macroeconomic data expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience receivables written either partly full reasonable expectation recovery receivables written group continues engage enforcement activities attempt recover receivable due recoveries made recognised profit loss trade lease receivables group applies simplified approach prescribed ifrs requirespermits use lifetime expected loss provision initial recognition receivables group measures allowance doubtful accounts equal credit losses expected lifetime trade lease receivables policy applicable january receivables carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments policy applicable january january group classifies financial instruments following measurement categories disclosed note amortised cost fair value oci fair value oci equity investments fair value profit loss including hedging instruments roche finance report roche group notes roche group consolidated financial statements classification depends groups business model managing financial assets contractual terms cash flows group reclassifies debt securities financial assets amortised cost business model managing assets changes initial recognition group measures financial asset fair value plus case financial asset fair value profit loss transaction costs directly attributable acquisition financial asset transaction costs financial assets carried fair value profit loss expensed profit loss amortised cost assets held collection contractual cash flows cash flows represent solely payments principal interest measured amortised cost less provision impairment gain loss debt security subsequently measured amortised cost part hedging relationship recognised profit loss asset derecognised impaired interest income financial assets included financial income using effective interest rate method assets amortised cost mainly comprised accounts receivable cash cash equivalents time accounts three months fair value comprehensive income fair value oci financial assets held collection contractual cash flows selling financial assets assets cash flows represent solely payments principal interest initially recorded subsequently carried fair value changes fair value recorded comprehensive income except recognition impairment gains losses interest revenue foreign exchange gains losses recognised profit loss financial asset derecognised cumulative gain loss previously recognised oci reclassified equity profit loss interest income financial assets included financial income using effective interest rate method fair value comprehensive income assets mainly comprised money market instruments debt securities equity investments fair value comprehensive income fair value oci equity investments private biotechnology companies kept part groups strategic alliance efforts assets subsequently measured fair value dividends recognised financial income profit loss unless dividend clearly represents recovery part cost investment net gains losses recognised oci included fair value reserve asset derecognised cumulative gain loss previously recognised oci reclassified within equity fair value reserve retained earnings never profit loss fair value profit loss financial assets whose performance evaluated fair value basis gain loss financial asset subsequently measured fair value profit loss part hedging relationship recognised profit loss presented within financial income expense period arises fair value profit loss assets mainly comprised equity investmentssecurities contingent consideration liabilities initially recorded subsequently carried fair value changes fair value recorded general administration within operating results income statement fair value profit loss hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense policy applicable january financial instruments classified following categories disclosed note availableforsale fair value hedging instruments fair value designated loans receivables availableforsale nonderivative financial assets either designated classified financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense roche finance report notes roche group consolidated financial statements roche group fair value designated nonderivative financial instruments designated fair value profit loss initial recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash equivalents change policies january following items financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value less transaction costs subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire impairment financial assets policy applicable january group recognises loss allowances expected credit losses ecl financial assets measured amortised cost debt securities measured fair value oci trade lease receivables group measures allowance doubtful accounts amount equal lifetime ecl debt securities carried fair value oci debt securities financial assets amortised cost determined low credit risk based external credit ratings counterparties group measures loss allowances amount equal month ecl group considers debt securities low credit risk credit risk rating equivalent globally understood definition investment grade group considers least baa moodys bbb standard poors credit risk debt securities carried fair value oci debt securities financial assets amortised cost increased significantly since initial recognition group measures loss allowances amount equal lifetime ecl group assumes credit risk instruments increased significantly days past due financial assets written either partially full realistic prospect recovery generally case group determines customer assets sources income could generate sufficient cash flows repay amounts subject writeoff however financial assets written still subject enforcement activities order comply groups policy recovery amounts due policy applicable january financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost fair value roche finance report roche group notes roche group consolidated financial statements impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions eligibility hedging hedged instruments formal designation documentation well hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future amount tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans roche finance report notes roche group consolidated financial statements roche group changes accounting policies group implemented following new standards including consequential amendments standards date initial application january ifrs financial instruments ifrs revenue contracts customers definition business amendments ifrs group also implemented various minor amendments existing standards interpretations material impact groups overall results financial position none new standards revised standards amended standards interpretations material impact groups overall results financial position nature effects changes relevant groups financial statements given ifrs financial instruments effective january group implemented ifrs financial instruments new standard replaces ias financial instruments recognition measurement standard deals classification recognition measurement including impairment financial instruments also introduces new hedge accounting model new standard results increased volume disclosure information annual financial statements classification measurement financial instruments previously marketable securities classified availableforsale ias new standard equity securities classified fair value profit loss debt securities money market instruments fair value comprehensive income oci time accounts three months amortised cost group elected classify certain strategic equity investments fair value oci strategic equity investments sold cumulative amount included fair value reserve transferred retained earnings impairment financial assets january group changed methodology assessing impairment financial assets incurred loss model used ias expected credit loss model used ifrs accordance transitional provisions ifrs group restated prior periods reassessed impairment allowances new approach january hedge accounting new standard also introduces new hedge accounting model requires hedge accounting relationships based upon groups risk management strategy objectives discontinued relationships longer qualify hedge accounting group applied revised hedge accounting guidance hedging relationships prospectively effect january hedge accounting relationships designated previous ias guidance continued valid hedge accounting relationships accordance ifrs transition approach group applied exemption full retrospective application classification measurement requirements including impairment meaning comparative results restated differences carrying amounts financial assets reclassification adjustments adoption ifrs recognised retained earnings reserves january accordingly information presented generally reflect requirements ifrs rather ias presentational changes result implementing ifrs group made number presentational changes statement comprehensive income statement changes equity notes roche finance report roche group notes roche group consolidated financial statements impact initial application ifrs impact initial application ifrs groups consolidated balance sheet groups consolidated equity follows revised roche group consolidated balance sheet selected items millions chf balance balance application january january ifrs revised accounts receivable deferred tax assets total net assets capital reserves attributable roche shareholders total equity revised roche group consolidated equity selected items millions chf application balance balance ifrs january january net tax revised retained earnings fair value reserves total equity reclassification within equity chf million net tax transferred fair value reserves retained earnings january related unrealised gains equity instrumentsinvestments due reclassification fair value profit loss previously classified availableforsale addition decrease chf million net tax retained earnings due additional bad debt allowance trade lease receivables resulting applying expected credit loss model used ifrs following table reconciles carrying amounts financial assets ias carrying amounts ifrs transition ifrs january reclassifications financial liabilities reclassifications financial instruments adoption ifrs millions chf remeasurement balance balance application january measurement category january ifrs revised original new ias ifrs current financial assets accounts receivable loans receivables amortised cost equity securities availableforsale fair value profit loss debt securities availableforsale fair value oci money market instruments availableforsale fair value oci time accounts three months availableforsale amortised cost derivative financial instruments fair value profit fair value profit loss loss financial current assets loans receivables amortised cost noncurrent financial assets equity investments fair value availableforsale fair value oci oci equity investments fair value availableforsale fair value profit profit loss loss financial noncurrent assets loans receivables amortised cost roche finance report notes roche group consolidated financial statements roche group ifrs revenue contracts customers effective january group implemented ifrs revenue contracts customers new standard replaces ias revenue ias construction contracts ifrs establishes comprehensive framework determining whether much revenue recognised also contains new requirements related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration received exchange goods services objective standard provide fivestep approach revenue recognition includes identifying contracts customers identifying performance obligations determining transaction prices allocating transaction prices performance obligations recognising revenue performance obligations satisfied judgement needs applied including making estimates assumptions multipleelement contracts identifying performance obligations constraining estimates variable consideration allocating transaction price performance obligation lease components particularly diagnostics business outlicensing agreements new standard results increased volume disclosure information annual financial statements changes introduced standard relevant roche group new standard provides additional requirements guidance relevant group notably following areas revenue licences intellectual property including salesbased royalties constraining estimates variable consideration eg development milestones providing material right receive additional goods free charge certain patient access programmes may regarded separate performance obligation material impact changes new standard also clarifies allocate sales including treatment discounts element multipleelements contracts recognise sales elements contracts entered diagnostics division typically include obligations instruments including provided leasing arrangements reagents consumables services requires use estimates assumptions judgement apply guidance practice material impact guidance outlicensing agreements pharmaceuticals division may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments licensing fees reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation answers new standard may different currently used new standard provides exemption salesbased royalties licences intellectual property continue recognised revenue underlying sales incurred transition approach use practical expedients group applied full retrospective method transition certain practical expedients permitted standard transition also used notably relief restate contracts began completed completed january relief provide disclosure requirement per ifrs paragraph comparative period amount transaction price allocated remaining performance obligations since new standard including use practical expedients modified timing amounts revenue recognised restatement necessary presentational changes result implementing ifrs group also made presentational change income statement include subtotal revenue created new note revenue note definition business amendments ifrs october international accounting standards board issued amendments ifrs business combinations amendments clarify definition business add optional concentration test aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets amendments mandatory may early adopted amendments particularly relevant many acquisitions carried group since value acquired companies often largely consists rights single product technology therefore effective january group early implemented amendments prospective application restatement comparative period information roche finance report roche group notes roche group consolidated financial statements note expanded renamed mergers acquisitions include transactions accounted business combinations asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations ifrs cash consideration paid asset acquisitions transaction date subsequent additional contingent payments made upon achievement performancerelated development milestones presented line asset acquisitions disclosed note subsequent consideration performancerelated development milestones transactions treated asset acquisitions recognised intangible assets specific milestones achieved previously intangible assets acquired asset acquisitions included line items purchase intangible assets statement cash flows additions note intangible assets future new revised standards group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position except effects implementation ifrs leases summarised ifrs leases group implement new standard effective january ifrs replace existing leases guidance including ias leases sets principles recognition measurement leases new standard also result increased volume disclosure information annual financial statements main effect group ifrs introduces single onbalance sheet lease accounting model lessees requires lessee recognise assets liabilities almost leases including operating leases group assessed potential impact expects carrying value leased assets increase approximately chf billion lease liabilities expected increase similar amount date implementation application new standard result part currently reported operating lease costs recorded interest expenses given leases involved current low interest rate environment group currently expect effect material group currently finalising exact impact new standard transition approach use practical expedients group apply cumulative catchup method transition therefore cumulative effect adopting ifrs recognised adjustment opening balance retained earnings january restatement comparative information practical expedients permitted standard also used notably reassess upon transition whether existing contract contains lease recognition exemptions shortterm leases leases lowvalue assets presentational changes result implementing ifrs group make number presentational changes notably present rightofuse assets separate line item balance sheet include lease liabilities current non current liabilities new note leases created include increased volume required disclosure information roche finance report report roche management internal control financial reporting roche holding ltd basel report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit consolidated financial statements opinion audited consolidated financial statements roche holding ltd subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement comprehensive income consolidated statement changes equity consolidated statement cash flows year ended notes consolidated financial statements including summary significant accounting policies opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law basis opinion conducted audit accordance swiss law international standards auditing isas swiss auditing standards responsibilities provisions standards described auditors responsibilities audit consolidated financial statements section report independent group accordance provisions swiss law requirements swiss audit profession well iesba code ethics professional accountants fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters chargebacks rebates sales returns us pharmaceuticals business carrying value intermune goodwill relating pharmaceuticals division carrying value product intangible assets uncertain tax positions acquisition flatiron health inc key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion matters roche finance report statutory auditors report roche group chargebacks rebates sales returns us pharmaceuticals business key audit matter response groups pharmaceuticals business makes sales various audit procedures included amongst others sample customers us fall certain commercial basis obtaining managements calculations accrued governmentmandated contracts purchasing liabilities provisions accounts receivable deductions reimbursement arrangements significant recalculating amounts validating reasonableness medicaid b drug discount program key assumptions used reference internal external group also provides right return us customers sources including terms applicable contracts certain products return periods cases us government pricing information historical chargebacks extend several years future arrangements rebates historical sales returns levels current result deductions gross amounts invoiced arriving trends revenue create obligations group provide customers chargebacks rebates give considered accuracy managements estimates credit sales returns estimated amounts deducted previous years comparing historical accrued liabilities gross sales recorded accrued liabilities rebates provisions accounts receivable deductions recorded provisions sales returns deduction actual settlements also assessed changes accounts receivable chargebacks estimates accrual rates used within estimates including based analyses existing contractual legislatively responding increase utilisation b drug mandated obligations historical trends groups discount program comparing accrual rates experience current chargeback rebate payment sales return trends management determined accrued liabilities deductions accounts receivable expected chargebacks considered adequacy groups revenue rebates predominantly medicaid chf recognition accounting policies including recognition million necessary december additionally measurement deductions gross sales relating provisions sales returns mainly relating products chargebacks rebates sales returns related near loss exclusivity chf million recorded disclosures december focused area arrangements complex establishing appropriate yearend position requires significant judgement estimation management assumptions required estimating provisions sales returns also made complicated given recent impending loss exclusivity us groups pharmaceutical products information chargebacks rebates sales returns us pharmaceuticals business refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note revenue note accounts receivable note current liabilities note provisions contingent liabilities roche finance report roche group statutory auditors report carrying value intermune goodwill relating pharmaceuticals division key audit matter response january group held goodwill chf audit procedures included amongst others assessing million arising past acquisitions pharmaceuticals groups forecasting procedures integrity division principally genentech intermune together discounted cash flow models management used smaller technology transactions product transactions prepare valuations challenged robustness goodwill tested annually impairment addition key assumptions used determine recoverable assessed impairment reporting date amounts including identification allocation cgu including managements reassessment cgus year management undertook reassessment year forecast cash flows growth rates cashgenerating units cgus used allocating discount rates based understanding commercial goodwill pharmaceuticals division management prospects products markets required apply judgement allocating goodwill commercialised appropriate businesses well assessing future performance prospects cgu following using valuation specialists assist reassessment management recorded impairment us evaluating assumptions methodologies respect intermune goodwill chf million used management particular relating discount rates comparing relevant assumptions impairment testing uses projections future cash flows industry economic forecasts addition identified based recent longterm forecasts approved analysed changes assumptions prior periods management including estimated sales volumes pricing made assessment consistency assumptions longterm forecasts projected five years performed comparison assumptions publicly available data also performed retrospective focused particular intermune goodwill light assessment accuracy managements past amount judgement estimation required projections comparing historical forecasts actual results impairment recorded year also assessed whether groups disclosures sensitivity outcome impairment assessment changes key assumptions reflect risks inherent valuation goodwill information carrying value goodwill relating pharmaceuticals division refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note goodwill roche finance report statutory auditors report roche group carrying value product intangible assets key audit matter response group significant product intangible assets audit procedures included amongst others challenging december chf million acquired robustness key assumptions used determine business combinations inlicensing arrangements recoverable amounts including forecast revenues useful comprise product intangibles use chf million lives discount rates challenge based amortised product intangibles available understanding commercial prospects individual use chf million amortised impairment products well relevant business areas markets assessment carried product intangibles operate used valuation specialists evidence asset may impaired assist us evaluating assumptions methodologies intangible assets yet available use also used management relation discount rates tested impairment annually made assessments relation key inputs projected pricing volumes products projected product intangibles use chf million predominantly share therapeutic area vitro diagnostic market relate acquired products launched comparing relevant assumptions industry forecasts key risk ability successfully commercialise reviewing analyst commentaries retrospective products concerned largest single intangible asset arose assessment accuracy previous projections acquisition intermune relates esbriet compared managements assumptions external data chf million focused product intangible available example case esbriet use previous impairments recorded performed sensitivity analysis individual intangible low level headroom assessment asset impairment models assess level sensitivity recoverability involves forecasting discounting key assumptions could focus work areas future cash flows inherently judgemental key assess managements allowance risk estimates assumptions include revenue growth timing impact loss exclusivity discount rates product intangibles yet available use audit development commercialisation competing included assessing reasonableness managements products drivers revenue growth include persistence assumptions regarding probability obtaining regulatory rate treatment rate market share approval comparison industry practice past history consideration groups internal governance product intangibles available use chf million approval processes also interviewed number mostly represent inprocess research development senior research development commercial personnel assets due inherent uncertainties research order understand challenge assumptions development processes intangible assets available use particularly risk impairment impairment assessment requires management make key assumptions judgements clinical technical commercial viability new products accordingly also focused audit work areas risks include inability achieve successful trial results obtain required clinical regulatory approvals highly competitive business environment therapeutic areas group significant assets research development information carrying value productrelated intangible assets refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assets roche finance report roche group statutory auditors report uncertain tax positions key audit matter response group operates across wide range different audit procedures included amongst others obtaining tax jurisdictions around world thus subject understanding uncertain tax positions inquiry occasional challenges local tax authorities respect employees tax department management crossborder transfer pricing arrangements goods affiliates reviewed documentation relation services financing transactionrelated tax matters correspondence tax authorities verify whether connection integration investments divestments tax exposures considered provided licensing contracts areas particular focus include necessary transfer pricing arrangements relating groups manufacturing supply chains significant items challenged managements judgement regarding eventual resolution national amount tax liabilities uncertain group tax authorities double taxation conflicts pending tax recognises accruals reflect managements best audits estimates tax exposures assistance estimate outcome based facts known local country tax specialists significant relevant jurisdiction group open tax transfer uncertain tax positions work included consideration pricing matters various tax authorities range thirdparty transfer pricing studies use possible outcomes broad december available past experience tax authorities group recognised current income tax liabilities respective jurisdiction additionally used tax chf million includes accruals uncertain specialists expertise assess appropriateness tax positions key assumptions made management conclude best estimate outcome focused area estimates amounts tax receivable payable require significant level audit approach included additional audit procedures expertise judgement performed group level consider significant uncertain tax positions particular transfer prices applied goods services intellectual property rights information uncertain tax positions refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note income taxes roche finance report statutory auditors report roche group acquisition flatiron health inc key audit matter response group acquired flatiron health inc flatiron health audit procedures relation acquisition flatiron april total consideration usd million health included amongst others inspection legal consideration primarily allocated intangible assets agreements supporting transaction also examined goodwill chf million chf million information contained within due diligence valuation respectively reports well internal management presentations board directors acquisition flatiron health required management apply judgement identifying valuing intangible challenged appropriateness methodology used assets allocation goodwill arising management value identified intangible assets transaction cashgenerating units benefitting compared useful economic life intangible synergies identified assets similar technology platforms based understanding technology platform business key assumptions relating valuation areas flatiron health operates addition intangible assets included revenue growth discount rate considered appropriate range alternative obsolescence competitive environment particular focused rates valuation flatiron healths technology platform required additional consideration relating applied support valuation specialists obsolescence rate evaluated key estimates assumptions used management purchase price allocation evaluation goodwill arising transaction attributed focused appropriateness discount rate roche pharmaceuticals cashgenerating unit applied key assumptions made regarding revenue reflects benefits groups oncology research growth competitive environment challenged development activities use flatiron healths assumptions based sector expertise reference realworld evidence transactions similar nature performing sensitivity analysis key assumptions throughout procedures held inquiries managements external valuers obtained understanding flatiron healths realworld evidence would used within roche business expected synergies justify level goodwill recognised acquisition assessed appropriateness managements decision allocate goodwill roche pharmaceuticals cashgenerating unit also assessed whether groups disclosures relation acquisition meet requirements relevant accounting standards information acquisition flatiron health inc refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note mergers acquisitions roche finance report roche group statutory auditors report information annual report board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon opinion consolidated financial statements cover information annual report express form assurance conclusion thereon connection audit consolidated financial statements responsibility read information annual report consider whether information materially inconsistent consolidated financial statements knowledge obtained audit otherwise appears materially misstated based work performed conclude material misstatement information required report fact nothing report regard responsibility board directors consolidated financial statements board directors responsible preparation consolidated financial statements give true fair view accordance ifrs provisions swiss law internal control board directors determines necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements board directors responsible assessing groups ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic alternative auditors responsibilities audit consolidated financial statements objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern roche finance report statutory auditors report roche group evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentation obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit consolidated financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group independent reasonable assurance report internal control financial reporting independent reasonable assurance report internal control financial reporting board directors roche holding ltd basel engaged board directors carry reasonable assurance engagement design implementation operating effectiveness system internal control financial reporting roche group place december management roche holding ltd assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso responsibilities board directors management board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting entitys internal control financial reporting process designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs entitys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate responsibilities responsibility examine design implementation effectiveness companys internal control financial reporting report thereon form independent reasonable assurance conclusion based evidence obtained conducted engagement accordance international standard assurance engagements isae assurance engagements audits reviews historical financial information issued international auditing assurance standards board standard requires plan perform procedures obtain reasonable assurance whether effective internal control financial reporting maintained material respects procedures selected depend judgement including assessment risks material misstatement design implementation effectiveness companys internal control financial reporting examination included obtaining understanding internal control financial reporting testing evaluating design implementation operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances roche finance report independent reasonable assurance report internal control financial reporting roche group independence quality control firm applies international standard quality control accordingly maintains comprehensive system quality control including documented policies procedures regarding compliance ethical requirements professional standards applicable legal regulatory requirements complied independence ethical requirements code ethics professional accountants issued international ethics standards board accountants founded fundamental principles integrity objectivity professional competence due care confidentiality professional behaviour conclusion conclusion formed basis subject matters outlined report believe evidence obtained sufficient appropriate provide basis conclusion opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group alternative performance measures financial information included financial review includes certain alternative performance measures apms accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms presented financial review relate performance current year comparative periods core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting impacts accounting merger acquisition transactions alliance arrangements see financial review excluded discontinued operations currently none excluded legal environmental cases see financial review excluded global issues outside healthcare sector beyond groups control excluded material treasury items major debt restructurings currently none excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary information core results reconciliation millions chf normali global intangibles alliance legal pension sation restruc amorti intangibles trans environ plan global ecp tax ifrs turing sation impairment actions mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf normali global intangibles alliance legal pension sation restruc amorti intangibles trans environ plan global ecp tax ifrs turing sation impairment actions mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report multiyear overview supplementary information roche group divisional core results reconciliation millions chf global intangibles alliance legal pension restruc amorti intangibles trans environ plan ifrs turing sation impairment actions mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf global intangibles alliance legal pension restruc amorti intangibles trans environ plan ifrs turing sation impairment actions mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business operating free cash flow calculated based ifrs operating profit adjusted certain cash items movements net working capital capital expenditures investments property plant equipment intangible assets operating free cash flow different cash flows operating activities defined ias includes capital expenditures within responsibility divisional management excludes income taxes paid within responsibility divisional management cash outflows defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflows financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments roche finance report multiyear overview supplementary information roche group operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review operating free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct investments property plant equipment investments intangible assets disposal property plant equipment disposal intangible assets pensions postemployment benefits add back total payments defined benefit plans deduct allocation payments operating free cash flow operating items operating free cash flow free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias deduct investments property plant equipment investments intangible assets disposal property plant equipment disposal intangible assets interest paid operating items treasury items free cash flow roche finance report roche group multiyear overview supplementary information supplementary information used calculate divisional operating free cash flow shown table divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda group use earnings interest tax depreciation amortisation ebitda either internal management reporting external communications opinion groups management operating free cash flow gives useful consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade receivables inventories certain noncash entries arising acquisition accounting pension accounting convenience readers use ebitda provided table starting point uses core results already exclude amortisation impairment goodwill intangible assets ebitda using core results millions chf pharmaceuticals diagnostics corporate group ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report multiyear overview supplementary information roche group net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment goodwill intangible assets net working capital longterm net operating assets minus provisions calculation net operating assets disclosed note annual financial statements shown tables net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets roche finance report roche group multiyear overview supplementary information net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt calculations including details movements current year shown table financial review net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earnings per share disclosures countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflated roche finance report roche securities roche group roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr standard poors index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche group roche securities number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors stock codes share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies ignificant shareholders hareholders equity fulltime equivalent employees contingent liabilities board executive shareholdings appropriation available earnings statutory auditors report general meeting roche holding ltd basel roche finance report roche holding ltd basel financial statements financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies interestbearing liabilities group companies shortterm liabilities total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities genussscheine nominal value roche finance report financial statements roche holding ltd basel income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income roche finance report roche holding ltd basel notes financial statements notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant accounting principles applied described company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments direct indirect investments company listed note roche group annual financial statements listing excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation ownership interests equal voting rights taxes direct taxes include corporate income capital taxes shareholders equity share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates roche finance report notes financial statements roche holding ltd basel equity instruments december company hold roche shares nonvoting equity securities none company neither purchased sold roche shares nonvoting equity securities companys subsidiaries meet definitions requirements article b co hold equity instruments within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co movement recognised amounts millions chf legal voluntary reserves retained earnings retained free special available equity total share capital earnings reserve reserve earnings instruments equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company roche finance report roche holding ltd basel notes financial statements controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis holding ag basel participation fulltime equivalent employees annual average number fulltime equivalent employees exceed ten people board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri certain members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine ch franz hoffmann j bell j brown p bulcke hauser rp lifton e oeri b poussot schwan b c suessmuth dyckerhoff c c pr voser total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative close relatives hauser held nonvoting equity securities genussscheine e rp lifton held roche american depositary receipts adrs eight adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july roche finance report notes financial statements roche holding ltd basel corporate executive committee end year members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan r diggelmann na na heuer na na c hippe ga keller b oday ca wilbur total equity compensation awards ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares c heuer held restricted stock units rsus whereof issued rsus terms vesting conditions awards disclosed note roche group annual financial statements close relatives heuer held roche nonvoting equity securities december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages ssars awards held december year issue total schwan heuer hippe ga keller oday ca wilbur total cec strike price chf expiry date mar mar mar mar mar mar mar close relatives heuer held ssars issued strike price chf expiry date march grant value per ssar chf restricted stock units rsus remuneration component corporate executive committee replaced awarding corresponding performance share plan psp awards rsu awards vest recipient three years thereafter non voting equity securities may remain blocked ten years december members corporate executive committee hold rsus except michael heuer disclosed roche finance report roche holding ltd basel notes financial statements december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end cycle performance targets achieved accordingly participants received none originally targeted shares total target number awards outstanding performance cycles december shown table roche performance share plan psp awards held december psp psp schwan heuer hippe ga keller oday b ca wilbur total cec allocation date feb feb heuer participating psp programme b potential awards reduced due resignation information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statements roche finance report appropriation available earnings roche holding ltd basel appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche finance report roche holding ltd basel statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit financial statements opinion audited financial statements roche holding ltd comprise balance sheet december income statement year ended notes financial statements including summary significant accounting policies opinion financial statements pages year ended december comply swiss law companys articles incorporation basis opinion conducted audit accordance swiss law swiss auditing standards responsibilities provisions standards described auditors responsibilities audit financial statements section report independent entity accordance provisions swiss law requirements swiss audit profession fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion report key audit matters based circular federal audit oversight authority key audit matters matters professional judgement significance audit financial statements current period determined key audit matters communicate report responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud error preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate entity cease operations realistic alternative auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis financial statements roche finance report statutory auditors report roche holding ltd basel part audit accordance swiss law swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made c onclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause entity cease continue going concern communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd annual report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products media relations market fluctuations currency exchange rates general tel financial market conditions uncertainties discovery email mediarelationsrochecom development marketing new products new uses existing products including without limitation negative results clinical investor relations trials research projects unexpected side effects pipeline tel marketed products increased government pricing pressures email investorrelationsrochecom interruptions production loss inability obtain adequate protection intellectual property rights litigation corporate sustainability committee loss key executives employees adverse tel publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified paperf hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom finance report e roche finance report journey finance report recovery woman shown cover roche finance report year appeared cover report well last year midst receiving treatment breast cancer photographed came powerfully cover year later enjoying life p e n n n v n p r n e r cancer modern care helps advanced analytics enable us roche expanding colla b effective treatments create wealth new data insights orations combining available previously innovative opportunities across strengths unique tools therapies allow woman entire product lifecycle rd partners elevate personalised cover picture carry value chain ultimately improve healthcare new level many life see back cover outcomes patients patients